Nature of Operations [Text Block]

1. The Company

Liquidity

In addition to the need for financing described above, the Company may take the following actions to support its liquidity needs through the remainder of 2016 and into 2017:

•

Shift focus to existing products and customers with significantly reduced investment in new product and commercial development efforts.

•

Reduce production activity at the Company’s Brotas manufacturing facility to levels only sufficient to satisfy volumes required for product revenues forecast from existing products and customers.

•

Reduce expenditures for third party contractors, including consultants, professional advisors and other vendors.

•

Reduce or delay uncommitted capital expenditures, including non-essential facility and lab equipment, and information technology projects.

•

Closely monitor the Company’s working capital position with customers and suppliers, as well as suspend operations at pilot plants and demonstration facilities.

Implementing this plan could have a negative impact on the Company's ability to continue its business as currently contemplated, including, without limitation, delays or failures in its ability to:

•

Achieve planned production levels;

•

Develop and commercialize products within planned timelines or at planned scales; and

•

Continue other core activities.

XML 25 R9.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
Note 2 - Summary of Significant Accounting Policies	Sep. 30, 2016
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying interim condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (or “GAAP”) and with the instructions for Form 10-Q and Regulation S-X. Accordingly, they do not include all of the information and notes required for complete financial statements. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Form 10-K for the fiscal year ended December 31, 2015 as filed with the Securities and Exchange Commission (or the “SEC”) on March 30, 2016. The unaudited condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The Company uses the equity method to account for investments in companies, if its investments provide it with the ability to exercise significant influence over operating and financial policies of the investee. Consolidated net income or loss includes the Company’s proportionate share of the net income or loss of these companies. Judgments made by the Company regarding the level of influence over each equity method investment include considering key factors such as the Company’s ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. Principles of Consolidation The condensed consolidated financial statements of the Company include the accounts of Amyris, Inc., its subsidiaries and two consolidated variable interest entities (or “VIEs”), with respect to which the Company is considered the primary beneficiary, after elimination of intercompany accounts and transactions. Disclosure regarding the Company’s participation in the VIEs is included in Note 7, "Joint Ventures and Noncontrolling Interest." Variable Interest Entities The Company has interests in joint venture entities that are VIEs. Determining whether to consolidate a VIE requires judgment in assessing (i) whether an entity is a VIE and (ii) if the Company is the entity’s primary beneficiary and thus required to consolidate the entity. To determine if the Company is the primary beneficiary of a VIE, the Company evaluates whether it has (i) the power to direct the activities that most significantly impact the VIE’s economic performance and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. The Company’s evaluation includes identification of significant activities and an assessment of its ability to direct those activities based on governance provisions and arrangements to provide or receive product and process technology, product supply, operations services, equity funding and financing and other applicable agreements and circumstances. The Company’s assessment of whether it is the primary beneficiary of its VIEs requires significant assumptions and judgment. Use of Estimates In preparing the unaudited condensed consolidated financial statements, management must make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Unaudited Interim Financial Information The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements, except for the impact of adoption of certain accounting standards as described below, and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. In the quarter ended March 31, 2016 the Company adopted Accounting Standards Update (“ASU”) No. 2015-01, Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items, ASU No. 2015-02, Consolidation (Topic 810), ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs , ASU 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40) and ASU No. 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements . Refer to Note 5. "Debt" for the impact of adoption of ASU No. 2015-03 on the Company's condensed consolidated financial statements. None of the other ASU’s adopted had a material impact on the Company’s condensed consolidated financial statements. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period. Recent Accounting Pronouncements In October 2016, the Financial Accounting Standards Board (or “FASB”) issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory on simplifying the accounting for income taxes related to intra-entity asset transfers. The new guidance allows an entity to recognize the tax expense from the sale of an asset in the seller’s tax jurisdiction when the transfers occurs, even though the pre-tax effects of that transaction are eliminated in consolidation. This guidance will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted only in the first quarter of 2017. The Company is evaluating the impact of adopting this new accounting standard update on the financial statements and related disclosures. In August 2016, the FASB issued ASU 2016-15 Classification of Certain Cash Receipts and Cash Payments on the statement of cash flows. The new guidance clarifies classification of certain cash receipts and cash payments in the statement of cash flows. This guidance will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017 and interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the impact of adopting this new accounting standard update on the financial statements and related disclosures. In June 2016, the Financial Accounting Standards Board (or “FASB”) issued ASU No. 2016-13, Allowance for Loan and Lease Losses (Financial Instruments - Credit Losses Topic 326.) . New impairment guidance for certain financial instruments (including trade receivables) will replace the current “incurred loss” model for estimating credit losses with a forward looking “expected loss” model. The ASU is effective for the Company for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early application is permitted as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is evaluating the impact of this standard on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting . This ASU identifies areas for simplification involving several aspects of accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur, as well as certain classifications on the statement of cash flows. This ASU will be effective for fiscal years beginning after December 15, 2016, and interim periods within those annual periods. The Company is currently assessing the potential impact of this ASU on its consolidated financial statements. Early adoption is permitted. The Company is currently assessing the potential impact of this ASU on its consolidated financial statements. Early adoption is permitted. In March 2016, the FASB issued ASU No. 2016-06, Contingent Put and Call Options in Debt Instruments . The amendments in this ASU clarify the requirements for assessing whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts. An entity performing the assessment under the amendments in this ASU is required to assess the embedded call (put) options solely in accordance with the four-step decision sequence. The ASU is effective for financial statements issued for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently assessing the potential impact of this ASU on its financial statements. In February 2016, the FASB issued Accounting Standards Update (or “ASU”) 2016-02- Leases with fundamental changes to how entities account for leases. Lessees will need to recognize a right-of-use asset and a lease liability for virtually all of their leases (other than leases that meet the definition of a short-term lease). The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for initial direct costs. Additional disclosures for leases will also be required. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. The new standard may materially impact the Company’s financial statements. In January 2016, the FASB issued ASU 2016-01 Financial Instruments-Overall , which address certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The amendments in this Update are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Earlier application is permitted under specific circumstances. The Company is currently assessing the potential impact of this standard on its consolidated financial statements. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory , which requires that inventory within the scope of the guidance be measured at the lower of cost and net realizable value. The new standard is being issued as part of the simplification initiative. Prior to the issuance of the standard, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin). The new guidance will be effective for fiscal years beginning after December 15, 2016, including interim periods within those years. Prospective application is required and early adoption is permitted. The Company is currently assessing the impact of adopting this new accounting standard on its financial statements. In August 2014, the FASB issued new guidance related to the disclosure around going concern. The new standard provides guidance around management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosure if substantial doubt exists. The new standard is effective for annual periods ending after December 15, 2016 and for annual periods and interim periods thereafter. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company's financial statements. In May 2014, the FASB issued new guidance related to revenue recognition. In March, April and May 2016, the FASB issued additional amendments to the new revenue guidance relating to reporting revenue on a gross versus net basis, identifying performance obligations, licensing arrangements, collectability, noncash consideration, presentation of sales tax, and transition. This new standard will replace all current GAAP guidance on this topic and eliminate all industry-specific guidance. The new revenue recognition update guidance provides a unified model to determine how revenue is recognized. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The FASB has issued several updates to the standard which i) clarify the application of the principal versus agent guidance (ASU 2016-08); ii) clarify the guidance on inconsequential and perfunctory promises and licensing (ASU 2016-10) and iii) narrow-scope improvements and practical expedients (ASU 2016-12). On July 9, 2015, the FASB voted to defer the effective date by one year to December 15, 2017 for interim and annual reporting periods beginning after that date and permitted early adoption of the standard, but not before the original effective date of December 15, 2016. Entities have the option of using either a full retrospective or a modified retrospective approach to adopt the new standard. Therefore, the new standard will be effective commencing with our quarter ending March 31, 2018. The Company is currently assessing the potential impact of this new standard on its consolidated financial statements and has not selected the transition method.

XML 26 R10.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value of Financial Instruments

9 Months Ended

Sep. 30, 2016

Financial Instruments Disclosure [Text Block]

3. Fair Value of Financial Instruments

The inputs to the valuation techniques used to measure fair value are classified into the following categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

	Level 1		Level 2		Level 3		Balance as of September 30, 2016
Financial Assets
Money market funds	$	59	$	—	$	—	$	59
Certificates of deposit		1,713		—		—		1,713
Total financial assets	$	1,772	$	—	$	—	$	1,772
Financial Liabilities
Loans payable (1)	$	—	$	34,146	$	—	$	34,146
Credit facilities (1)		—		19,310		—		19,310
Convertible notes (1)		—		—		109,885		109,885
Compound embedded derivative liabilities		—		—		3,827		3,827
Currency interest rate swap derivative liability		—		3,471		—		3,471
Total financial liabilities	$	—	$	56,927	$	113,712	$	170,639

(1)

These liabilities are carried on the condensed consolidated balance sheet on a historical cost basis.

As of December 31, 2015, the Company’s financial assets and financial liabilities are presented below at fair value and were classified within the fair value hierarchy as follows (in thousands):

	Level 1		Level 2		Level 3		Balance as of December 31, 2015
Financial Assets
Money market funds	$	2,078	$	—	$	—	$	2,078
Certificates of deposit		1,520		—		—		1,520
Total financial assets	$	3,598	$	—	$	—	$	3,598
Financial Liabilities
Loans payable (1)	$	—	$	9,541	$	—	$	9,541
Credit facilities (1)		—		34,893		—		34,893
Convertible notes (1)		—		—		96,291		96,291
Compound embedded derivative liabilities		—		—		46,430		46,430
Currency interest rate swap derivative liability		—		5,009		—		5,009
Total financial liabilities	$	—	$	49,443	$	142,721	$	192,164

_______

(1)

These liabilities are carried on the consolidated balance sheet on a historical cost basis (noting that the Remaining Notes subject to the Maturity Treatment Agreement were revalued to fair value on July 29, 2015, see Note 5 “Debt” for details).

The following table provides a reconciliation of the beginning and ending balances for the convertible notes disclosed at fair value using significant unobservable inputs (Level 3) (in thousands):

	2016
Balance at January 1	$	96,291
Additions of convertible notes		13,000
Conversion/extinguishment of convertible notes		(21,579	)
Change in fair value of convertible notes		22,173
Balance at September 30	$	109,885

Derivative Instruments

	2016
Balance at January 1	$	46,430
Derecognition on conversion/extinguishment		(2,734	)
Gain from change in fair value of derivative liabilities		(39,869	)
Balance at September 30	$	3,827

The market-based assumptions and estimates used in valuing the compound embedded derivative liabilities include amounts in the following ranges/amounts:

	September 30, 2016			September 30, 2015
Risk-free interest rate	0.20%	-	0.84%	0.93%	-	1.07%
Risk-adjusted yields	17.30%	-	27.43%	24.40%	-	39.90%
Stock-price volatility		45%			45%
Probability of change in control		5%			5%
Stock price		$0.58			$2.01
Credit spread	16.49%	-	26.60%	28.81%	-	38.83%
Estimated conversion dates	2016	-	2019	2015	-	2019

	Income Statement Classification	Three Months Ended September 30,						Nine Months Ended September 30,
Type of Derivative Contract		2016			2015			2016		2015
Currency interest rate swap	Gain (loss) from change in fair value of derivative instruments	$	(145	)	$	(1,796	)	$	1,957	$	(3,201	)

Derivative instruments measured at fair value as of September 30, 2016 and December 31, 2015, and their classification on the condensed consolidated balance sheets are as follows (in thousands):

	September 30, 2016		December 31, 2015
Fair market value of compound embedded derivative liabilities	$	3,827	$	46,430
Fair value of swap obligations		3,471		5,009
Total derivative liabilities	$	7,298	$	51,439

XML 27 R11.htm IDEA: XBRL DOCUMENT

Note 4 - Balance Sheet Components

9 Months Ended

Sep. 30, 2016

Supplemental Balance Sheet Disclosures [Text Block]

4. Balance Sheet Components

Inventories, net

Inventories, net are stated at the lower of cost or market and comprise of the following (in thousands):

	September 30, 2016		December 31, 2015
Raw materials	$	2,664	$	2,204
Work-in-process		1,809		3,583
Finished goods		3,426		5,099
Inventories, net	$	7,899	$	10,886

Property, Plant and Equipment, net

Property, plant and equipment, net is comprised of the following (in thousands):

	September 30, 2016			December 31, 2015
Machinery and equipment	$	85,538		$	72,876
Leasehold improvements		38,791			38,519
Computers and software		9,545			9,117
Buildings		4,718			3,922
Furniture and office equipment		2,335			2,234
Vehicles		195			215
Construction in progress		6,430			5,736
		147,552			132,619
Less: accumulated depreciation and amortization		(84,459	)		(72,822	)
Property, plant and equipment, net	$	63,093		$	59,797

Other Assets (non-current)

Other assets are comprised of the following (in thousands):

	September 30, 2016		December 31, 2015
Recoverable taxes from Brazilian government entities	$	11,955	$	8,887
Deposits on property and equipment, including taxes		292		243
Other		1,410		1,227
Total other assets	$	13,657	$	10,357

Accrued and Other Current Liabilities

Accrued and other current liabilities are comprised of the following (in thousands):

	September 30, 2016		December 31, 2015
Withholding tax related to conversion of related party notes	$	4,964	$	4,723
Professional services		5,406		4,017
SMA relocation accrual		4,380		3,641
Accrued interest		8,283		1,984
Tax-related liabilities		2,325		2,505
Accrued vacation		1,932		2,023
Payroll and related expenses		4,268		3,122
Deferred rent, current portion		1,110		1,111
Contractual obligations to contract manufacturers		680		—
Fair value swap short-term		586		—
Other		978		1,142
Total accrued and other current liabilities	$	34,912	$	24,268

XML 28 R12.htm IDEA: XBRL DOCUMENT

Note 5 - Debt and Mezzanine Equity

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Text Block]

5. Debt and Mezzanine Equity

Debt and mezzanine equity are comprised of the following (in thousands):

	September 30, 2016			December 31, 2015

Senior secured loan facility	$	28,438		$	31,590
BNDES credit facility		1,471			1,956
FINEP credit facility		777			840
Total credit facilities		30,686			34,386
Convertible notes		68,533			61,233
Related party convertible notes		40,611			42,749
Related party loan payable		22,847			—
Loans payable		12,954			13,606
Total debt		175,631			151,974
Less: current portion		(75,016	)		(36,281	)
Long-term debt	$	100,615		$	115,693
Mezzanine equity (1)		5,000			—

_____________

(1)	See Note 8, "Significant Agreements" for details regarding the Bill & Melinda Gates Foundation Investment, classified as mezzanine equity.

Senior Secured Loan Facility

BNDES Credit Facility

FINEP Credit Facility

Convertible Notes

Fidelity

2014 Rule 144A Convertible Note Offering

2015 Rule 144A Convertible Note Offering

upon the Company’s election to pay interest on the 2015 144A Notes in shares of common stock and upon the Company’s election to pay the Early Conversion Payment in shares of common stock in an aggregate amount in excess of

38,415,626 shares of the Company’s common stock was subject to stockholder approval, which was obtained on May 17, 2016. With exceptions for certain existing debt, refinancing of such debt and certain other exclusions and waivers, the 2015 144A Notes provide that, as long as the aggregate outstanding principal amount of the 2015 144A Notes exceeds $25.0 million, the Company's outstanding unsecured debt at any time cannot exceed $200.0 million and its secured debt cannot exceed the greater of $65.0 million or 30% of its consolidated total assets.

2016 Convertible Note Offering

$2 Million Note

”), representing the remaining 2016 Convertible Notes provided for in the May 2016 Purchase Agreement, on or before December 31, 2016. On October 13, 2016, the Company issued and sold the $2 Million Note to the purchaser for proceeds to the Company of $2.0 million. See Note 18, “Subsequent Events” for additional details regarding the issuance of the $2 Million Note.

Related Party Convertible Notes

Total R&D Convertible Notes

•

August 2013 Financing Convertible Notes and Temasek Bridge Note

2014 144A Notes Sold to Related Parties

Loans Payable

Exchange (debt conversion)

On July 29, 2015, the Company closed the "Exchange" pursuant to that certain Exchange Agreement, dated as of July 26, 2015 (or the “Exchange Agreement”), among the Company, Temasek and Total.

Under the Exchange Agreement, Total also received at the closing the following warrants, each with a five-year term:

•

A warrant to purchase 18,924,191 shares of the Company’s Common Stock (or the “Total Funding Warrant”).

•

Additionally, under the Exchange Agreement, Temasek received the following warrants:

•

A warrant to purchase 14,677,861 shares of the Company’s common stock. (the “Temasek Exchange Warrant”).

•

The exercisability of all of the Exchange Warrants was subject to stockholder approval, which was obtained on September 17, 2015.

Maturity Treatment Agreement

February 2016 Private Placement

June 2016 Private Placement

See Note 18, “Subsequent Events” for details regarding debt-related financing transactions completed subsequent to September 30, 2016.

Letters of Credit

Future minimum payments under the debt agreements as of September 30, 2016 are as follows (in thousands):

Years ending December 31:	Related Party Convertible Debt			Convertible Debt			Loans Payable			Related Party Loans payable		Credit Facility			Total
2016 (remaining three months)	$	312		$	3,240		$	1,770		$	844	$	33,234		$	39,400
2017		4,837			23,562			2,870			26,257		1,551			59,077
2018		13,937			17,736			2,450			—		322			34,445
2019		26,080			79,937			2,342			—		78			108,437
2020		—			—			2,234			—		—			2,234
Thereafter		—			—			3,314			—		—			3,314
Total future minimum payments		45,166			124,475			14,980			27,101		35,185			246,907
Less: amount representing interest (1)		(4,555	)		(55,942	)		(2,026	)		(4,254		(4,499	)		(71,276	)
Present value of minimum debt payments		40,611			68,533			12,954			22,847		30,686			175,631
Less: current portion present value of minimum debt payments		(3,611	)		(15,357	)		(3,275	)		(22,847		(29,926	)		(75,016	)
Noncurrent portion of debt	$	37,000		$	53,176		$	9,679		$	—	$	760		$	100,615

______________

In the quarter ended March 31, 2016, the Company adopted ASU 2015-03,

Interest - Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs

, which requires debt issuance costs previously reported as a deferred charge within other noncurrent assets and prepaid expenses and other current assets to be presented as a direct reduction from the carrying amount of debt, consistent with debt discounts, applied retrospectively for all periods presented. As of December 31, 2015, this resulted in the reduction of noncurrent debt by $2.8 million, current debt by $1.4 million, other noncurrent assets by $2.8 million and prepaid expenses and other current assets by $1.4 million.

XML 29 R13.htm IDEA: XBRL DOCUMENT

Note 6 - Commitments and Contingencies

9 Months Ended

Sep. 30, 2016

Commitments Contingencies and Guarantees [Text Block]

6. Commitments and Contingencies

Lease Obligations

Future minimum payments under the Company's lease obligations as of September 30, 2016, are as follows (in thousands):

Years ending December 31:	Capital Leases			Operating Leases		Total Lease Obligations
2016 (remaining three months)	$	471		$	1,762	$	2,233
2017		525			6,888		7,413
2018		28			6,890		6,918
2019		—			6,777		6,777
2020		—			7,008		7,008
Thereafter		—			18,210		18,210
Total future minimum lease payments		1,024		$	47,535	$	48,559
Less: amount representing interest		(26	)
Present value of minimum lease payments		998
Less: current portion		(942	)
Long-term portion	$	56

Guarantor Arrangements

Purchase Obligations

Other Matters

XML 30 R14.htm IDEA: XBRL DOCUMENT

Note 7 - Joint Ventures and Noncontrolling Interests

9 Months Ended

Sep. 30, 2016

Equity Method Investments and Joint Ventures Disclosure [Text Block]

7. Joint Ventures and Noncontrolling Interests

Novvi LLC

Total Amyris BioSolutions B.V.

SMA Indústria Química S.A.

Glycotech

(In thousands)	September 30, 2016		December 31, 2015
Assets	$	493	$	6,993
Liabilities	$	257	$	1,221

The change in noncontrolling interest for the nine months ended September 30, 2016 and 2015, is summarized below (in thousands):

	2016			2015
Balance at January 1	$	391		$	611
Foreign currency translation adjustment		—			(393	)
Income attributable to noncontrolling interest		—			78
Acquisition of noncontrolling interest		(277	)		—
Balance at September 30	$	114		$	296

XML 31 R15.htm IDEA: XBRL DOCUMENT

Note 8 - Significant Agreements	9 Months Ended
Note 8 - Significant Agreements	Sep. 30, 2016
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	8. Significant Agreements Research and Development Activities Total Collaboration Arrangement In June 2010, the Company entered into a technology license, development, research and collaboration agreement (or the “Total Collaboration Agreement”) with Total Gas & Power USA Biotech, Inc., an affiliate of Total. This agreement provided for joint collaboration on the development of products through the use of the Company’s synthetic biology platform. In November 2011, the Company entered into a first amendment of the Total Collaboration Agreement with respect to development and commercialization of Biofene for fuels. This represented an expansion of the initial collaboration with Total, and established a global, exclusive collaboration for the development of Biofene for fuels and a framework for the creation of a joint venture to manufacture and commercialize Biofene for diesel. In addition, a limited number of other potential products were subject to development by the joint venture on a non-exclusive basis. The first amendment provided for an exclusive strategic collaboration for the development of renewable diesel products and contemplated that the parties would establish a joint venture (or the “JV”) for the production and commercialization of such renewable diesel products on an exclusive, worldwide basis. In addition, the first amendment contemplated providing the JV with the right to produce and commercialize certain other chemical products on a non-exclusive basis. The first amendment further provided that definitive agreements to form the JV had to be in place by March 31, 2012 or such other date as agreed to by the parties or the renewable diesel program, including any further collaboration payments by Total related to the renewable diesel program, would terminate. In the second quarter of 2012, the parties extended the deadline to June 30, 2012, and, through June 30, 2012, the parties were engaged in discussions regarding the structure of future payments related to the program, until the first amendment was superseded by a second amendment in July 2012 (as further described below). Pursuant to the first amendment, Total agreed to fund the following amounts: (i) the first $30.0 million in research and development costs related to the renewable diesel program incurred since August 1, 2011, which amount would be in addition to the $50.0 million in research and development funding contemplated by the Total Collaboration Agreement, and (ii) for any research and development costs incurred following the JV formation date that were not covered by the initial $30.0 million, an additional $10.0 million in 2012 and up to an additional $10.0 million in 2013, which amounts would be considered part of the $50.0 million contemplated by the Total Collaboration Agreement. In addition to these payments, Total further agreed to fund 50% of all remaining research and development costs for the renewable diesel program under the Amendment. In July 2012, the Company entered into a second amendment of the Total Collaboration Agreement that expanded Total’s investment in the Biofene collaboration, incorporated the development of certain JV products for use in diesel and jet fuel into the scope of the collaboration, and changed the structure of the funding from Total for the collaboration by establishing a convertible debt structure for the collaboration funding (see Note 5, “Debt”). In connection with such second amendment Total and the Company also executed certain other related agreements. Under these agreements (collectively referred to as the “Total Fuel Agreements”), the parties would grant exclusive manufacturing and commercial licenses to the JV for the JV products (diesel and jet fuel from Biofene) when the JV was formed. The licenses to the JV were to be consistent with the principle that development, production and commercialization of the JV products in Brazil would remain with Amyris unless Total elected, after formation of the operational JV, to have such business contributed to the joint venture. Further, as part of the Total Fuel Agreements, Total's royalty option contingency related to diesel was removed and the jet fuel collaboration was combined with the expanded Biofene collaboration. As a result, $46.5 million of payments previously received from Total that had been recorded as an advance from Total were no longer contingently repayable. Of this amount, $23.3 million was treated as a repayment by the Company and included as part of the senior unsecured convertible promissory note issued to Total in July 2012 and the remaining $23.2 million was recorded as a contract to perform research and development services, which was offset by the reduction of the capitalized deferred charge asset of $14.4 million resulting in the Company recording revenue from a related party of $8.9 million in 2012. On March 21, 2016, the Company and Total consummated a restructuring of the JV pursuant to a letter agreement dated July 26, 2015, as amended on February 12, 2016, which restructuring included, among other things, the parties amending certain of the Total Fuel Agreements and the Company selling part of its ownership stake in the JV to Total in exchange for Total cancelling certain outstanding indebtedness issued to Total by the Company. In July 2016, the Company and Total agreed to extend the term of the Total Collaboration Agreement from July 31, 2016 to March 1, 2017 pursuant to the terms of the Total Collaboration Agreement. See Note 5, "Debt" and Note 7, "Joint Ventures and Noncontrolling Interest" for further details of the Company’s relationship with Total. F&F Collaboration Agreement In March 2013, the Company entered into a Master Collaboration Agreement (or, as amended in July 2015, the “F&F Collaboration Agreement”) with a collaboration partner to establish a collaboration arrangement for the development and commercialization of multiple renewable flavors and fragrances compounds. Under the F&F Collaboration Agreement, except for rights granted under pre-existing collaboration relationships, the Company granted the collaboration partner exclusive access to specified Company intellectual property for the development and commercialization of flavors and fragrances compounds in exchange for research and development funding and a profit sharing arrangement. The F&F Collaboration Agreement superseded and expanded the November 2010 Master Collaboration and Joint Development Agreement between the Company and the collaboration partner. The F&F Collaboration Agreement provided for annual, up-front funding to the Company by the collaboration partner of $10.0 million for each of the first three years of the collaboration. Payments of $10.0 million were received by the Company in each of March 2013, 2014 and 2015. The F&F Collaboration Agreement contemplates additional funding by the collaboration partner of up to $5.0 million under four potential milestone payments, as well as additional funding by the collaboration partner on a discretionary basis. Through September 2016, the Company had achieved the third performance milestone under the F&F Collaboration Agreement and recognized collaboration revenues of $1.3 million under the F&F Collaboration Agreement for the three months ended September 30, 2016 and $5.5 million for the nine months ended September 30, 2016. The F&F Collaboration Agreement does not impose any specific research and development obligations on either party after year six, but provides that if the parties mutually agree to perform research and development activities after year six, the parties will fund such activities equally. Under the F&F Collaboration Agreement, the parties agreed to jointly select target compounds, subject to final approval of compound specifications by the collaboration partner. During the development phase, the Company would be required to provide labor, intellectual property and technology infrastructure and the collaboration partner would be required to contribute downstream polishing expertise and market access. The F&F Collaboration Agreement provides that the Company will own research and development and strain engineering intellectual property, and the collaboration partner will own blending and, if applicable, chemical conversion intellectual property. Under certain circumstances, such as the Company’s insolvency, the collaboration partner would gain expanded access to the Company’s intellectual property. The F&F Collaboration Agreement contemplates that, following development of flavors and fragrances compounds, the Company will manufacture the initial target molecules for the compounds and the collaboration partner will perform any required downstream polishing and distribution, sales and marketing. The F&F Collaboration Agreement provides that the parties will mutually agree on a supply price for each compound developed under the agreement and, subject to certain exceptions, will share product margins from sales of each such compound on a 70/30 basis (70% for the collaboration partner) until the collaboration partner receives $15.0 million more than the Company in the aggregate from such sales, after which time the parties will share the product margins 50/50. The Company also agreed to pay a one-time success bonus to the collaboration partner of up to $2.5 million if certain commercialization targets are met. In September 2014, the Company entered into a supply agreement with the collaboration partner for a compound developed under the F&F Collaboration Agreement. The Company recognized $0.1 million and $1.3 million of revenues from product sales under this agreement for the three months ended September 30, 2016 and 2015, respectively and $4.7 million and $1.3 million for the nine months ended September 30, 2016 and 2015. Michelin and Braskem Collaboration Agreements In June 2014, the Company entered into a collaboration agreement with Braskem S.A. (or “Braskem”) and Manufacture Francaise de Pnematiques Michelin (or “Michelin”) to collaborate to develop the technology to produce and possibly commercialize renewable isoprene. The term of the collaboration agreement commenced on June 30, 2014 and will continue, unless earlier terminated in accordance with the agreement, until the first to occur of (i) the date that is three years following the actual date on which a work plan is completed, which date is estimated to occur on or about December 30, 2020, or (ii) the date of the commencement of commissioning of a production plant for the production of renewable isoprene. The June 2014 collaboration agreement terminated and superseded the September 2011 collaboration agreement between the Company and Michelin and, as a result of the signing of the June 2014 collaboration agreement, the upfront payment by Michelin of $5.0 million under the September 2011 collaboration agreement was rolled forward into the new collaboration agreement as Michelin’s funding towards the research and development activities to be performed under the new collaboration agreement. Braskem contributed $4.0 million of funding to the research and development activities under the June 2014 collaboration agreement, of which $2.0 million was received in July 2014 and $2.0 million was received in January 2015. For this collaboration agreement, the Company recognized collaboration revenues of zero and zero for the three months ended September 30, 2016 and 2015, respectively, and $0.1 million and $1.9 million for the nine months ended September 30, 2016 and 2015, respectively. As of September 30, 2016 and 2015, $6.5 million and $6.3 million, respectively, of deferred revenues were recorded in the condensed consolidated balance sheet related to these agreements. Kuraray Collaboration Agreement and Securities Purchase Agreement In March 2014, the Company entered into the Second Amended and Restated Collaboration Agreement with Kuraray Co., Ltd (or “Kuraray”) in order to extend the term of the original collaboration agreement between the Company and Kuraray dated July 21, 2011 for an additional two years and add additional fields and products to the scope of development. In consideration for the Company’s agreement to extend the term of the original collaboration agreement and add additional fields and products, Kuraray agreed to pay the Company $4.0 million in two equal installments of $2.0 million. The first installment was paid on April 30, 2014 and the second installment was due on April 30, 2015. In connection with entering into the Second Amended and Restated Collaboration Agreement, Kuraray signed a Securities Purchase Agreement in March 2014 to purchase 943,396 shares of the Company's common stock at a price per share of $4.24 per share, which shares were sold and issued in April 2014 for aggregate cash proceeds to the Company of $4.0 million. In March 2015, the Company and Kuraray entered into the First Amendment to the Second Amended and Restated Collaboration Agreement to extend the term of the original collaboration agreement until December 31, 2016 and to accelerate payment to the Company of the second installment of $2.0 million due from Kuraray under the Second Amended and Restated Collaboration Agreement to March 31, 2015. The Company recognized collaboration revenues of $0.4 million and $0.3 million for the three months ended September 30, 2016 and 2015, and $1.1 million and $1.2 million for the nine months ended September 30, 2016 and 2015, respectively, under this agreement. DARPA In September 2015, the Company entered into a Technology Investment Agreement (or the “2015 TIA”) with The Defense Advanced Research Projects Agency (or “DARPA”), under which the Company, with the assistance of five specialized subcontractors, will work to create new research and development tools and technologies for strain engineering and scale-up activities. The program that is the subject of the 2015 TIA will be performed and funded on a milestone basis, where DARPA, upon the Company’s successful completion of each milestone event in the 2015 TIA, will pay the Company the amount set forth in the 2015 TIA corresponding to such milestone event. Under the 2015 TIA, the Company and its subcontractors could collectively receive DARPA funding of up to $35.0 million over the program’s four year term if all of the program’s milestones are achieved. In conjunction with DARPA’s funding, the Company and its subcontractors are obligated to collectively contribute approximately $15.5 million toward the program over its four year term (primarily by providing specified labor and/or purchasing certain equipment). The Company can elect to retain title to the patentable inventions it produces under the program, but DARPA receives certain data rights as well as a government purposes license to certain of such inventions. Either party may, upon written notice and subject to certain consultation obligations, terminate the 2015 TIA upon a reasonable determination that the program will not produce beneficial results commensurate with the expenditure of resources. The Company recognized collaboration revenues of $1.3 million and zero under this agreement for the three months ended September 30, 2016 and 2015, respectively, and $4.8 million and zero for the nine months ended September 30, 2016 and 2015, respectively. Givaudan Collaboration Agreement In June 2016, the Company entered into a Collaboration Agreement with Givaudan International, SA (or “Givaudan”), a global flavors and fragrances company, to establish a collaboration for the development and commercialization of certain renewable compounds for use in the fields of active cosmetics and flavors. Under this collaboration agreement, the Company will use its labor, intellectual property and technology infrastructure to develop and commercialize certain compounds for Givaudan. In exchange, Givaudan will pay to the Company $12.0 million in semi-annual installments of $3.0 million each, beginning on June 30, 2016. The Company received the first installment of $3.0 million on June 30, 2016 and this amount was recognized in deferred revenue as of that date. Pursuant to this collaboration agreement, the Company will grant to Givaudan an exclusive license to the intellectual property that the Company generates under the agreement. Such license will include the rights to make, use and sell compounds in the active cosmetics and flavors fields, and is subject to certain ‘claw back’ rights by the Company if a compound is not commercialized by Givaudan during the term of the agreement. The Company will also grant to Givaudan non-exclusive rights to certain portions of the Company’s existing intellectual property in order to facilitate activities under the agreement. Givaudan, on the other hand, will grant to the Company a non-exclusive license to the intellectual property that is generated under the agreement. Such non-exclusive license will include the rights to make, use and sell compounds in all fields except active cosmetics and flavors. Subject to certain rights granted to a third party, Givaudan will have the exclusive right to commercialize the compounds in the active cosmetics and flavors markets during the term of the agreement. Further, the Company has agreed that it will not assist any third party in the development or commercialization of other compounds for sale or use in the active cosmetics or flavors markets during the term of the agreement. In addition, the agreement contemplates that the Company will be the primary supplier of commercial quantities of the compounds to Givaudan pursuant to supply agreements to be mutually negotiated by the parties. The Company recognized collaboration revenues of $1.6 million under this agreement for the three months ended September 30, 2016. Ginkgo Initial Strategic Partnership Agreement and Collaboration Agreement In June 2016, the Company entered into an Initial Strategic Partnership Agreement (or the “Initial Ginkgo Agreement”) with Ginkgo Bioworks, Inc. (or “Ginkgo”), pursuant to which the Company licensed certain intellectual property to Ginkgo in exchange for a fee of $20.0 million, to be paid by Ginkgo to the Company in two installments, and a ten percent royalty. The first installment of $15.0 million was received on July 25, 2016. The second installment, in the amount of $5.0 million is to be received, based upon the satisfaction of certain conditions as set forth below, by March 31, 2017. The Company recognized $15 million of collaboration revenue under the Initial Ginkgo Agreement for the three months ended September 30, 2016. Furthermore, in connection with the Initial Ginkgo Agreement, on June 29, 2016, the Company received a deferment of all scheduled principal repayments under the Senior Secured Loan Facility, the lender and administrative agent under which is an affiliate of Ginkgo, as well as a waiver of the Minimum Cash Covenant, through October 31, 2016. In addition, addition, pursuant to the Initial Ginkgo Agreement, the Company and Ginkgo agreed to pursue the negotiation and execution of a detailed definitive partnership and license agreement setting forth the terms of a commercial partnership and collaboration arrangement between the parties (or the “Collaboration”) and, in connection with the entry into the Initial Ginkgo Agreement, on June 29, 2016, the Company received a deferment of all scheduled principal repayments under the Senior Secured Loan Facility, as well as a waiver of the Minimum Cash Covenant, through October 31, 2016. Furthermore, pursuant to the Initial Ginkgo Agreement, in connection with the execution of the definitive agreement for the Collaboration, (i) the Company would issue to Ginkgo an option to purchase five million shares of common stock of the Company at an exercise price of $0.50, exercisable for one year from the date of issuance and (ii) the parties would effect an amendment of the Company’s Senior Secured Loan Facility to (x) extend the maturity date of all outstanding loans under the Senior Secured Loan Facility, (y) waive any required amortization payments under the Senior Secured Loan Facility until maturity and (z) eliminate the Minimum Cash Covenant under the Senior Secured Loan Facility. On August 6, 2016, the Company issued to Ginkgo a warrant to purchase five million shares of the Company’s common stock at an exercise price of $0.50 per share, exercisable for one year from the date of issuance. The warrant was issued prior to the execution of the definitive agreement for the Collaboration in connection with the transfer of certain information technology from Ginkgo to the Company. On September 30, 2016, the Company and Ginkgo entered into a Collaboration Agreement (or the “Ginkgo Collaboration Agreement”) setting forth the terms of the Collaboration, under which the parties will collaborate to develop, manufacture and sell commercial products and will share in the value created thereby. The Ginkgo Collaboration Agreement provides that, subject to certain exceptions, all third party contracts for the development of chemical small molecule compounds whose manufacture is enabled by the use of microbial strains and fermentation technologies that are entered into by the Company or Ginkgo during the term of the Ginkgo Collaboration Agreement will be subject to the Collaboration and the approval of the other party (not to be unreasonably withheld). Responsibility for the engineering and small-scale process development of the newly developed products will be allocated between the parties on a project-by-project basis, and the Company will be principally responsible for the commercial scale-up and production of such products, with each party generally bearing their own respective costs and expenses relating to the Collaboration, including capital expenditures. Notwithstanding the foregoing, subject to the Company sourcing funding and breaking ground on a new production facility by March 30, 2017, Ginkgo will pay the Company a fee of $5 million on or before March 31, 2017. Under the Ginkgo Collaboration Agreement, subject to certain exceptions, including excluded or refused products and cost savings initiatives, the profit on the sale of products subject to the Ginkgo Collaboration Agreement as well as cost-sharing, milestone and “value-creation” payments associated with the development and production of such products will be shared equally between the parties. The parties also agreed to provide each other with a license and other rights to certain intellectual property necessary to support the development and manufacture of the products under the Collaboration, and also to provide each other with access to certain other intellectual property useful in connection with the activities to be undertaken under the Ginkgo Collaboration Agreement, subject to certain carve-outs. The initial term of the Ginkgo Collaboration Agreement is three years, and will automatically renew for successive one-year terms unless either party provides written notice of termination not less than 90 days prior to the expiration of the then-current term, subject to the right of the parties to terminate the Ginkgo Collaboration Agreement by mutual agreement, in the event of a material breach by the other party, or in the event the other party undergoes a change of control. In addition, the Ginkgo Collaboration Agreement provides that the parties will evaluate the performance of the Collaboration as of the 18-month anniversary of the Ginkgo Collaboration Agreement, and if either party has been repeatedly unable to perform or meet its commitments under the Ginkgo Collaboration Agreement, the other party will have the right to terminate the Ginkgo Collaboration Agreement on 30 days written notice. The Ginkgo Collaboration Agreement contains customary representations and warranties of the parties, as well as customary terms and provisions regarding, among other things, indemnification, dispute resolution, governing law and confidentiality. See Note 18, “Subsequent Events” for additional details regarding the amendment to the Company’s Senior Secured Loan Facility entered into in connection with the execution of the Ginkgo Collaboration Agreement. Financing Agreements Bill & Melinda Gates Foundation Investment On April 8, 2016, the Company entered into a Securities Purchase Agreement with the Bill & Melinda Gates Foundation (the “Gates Foundation”), pursuant to which the Company agreed to sell and issue 4,385,964 shares of its common stock to the Gates Foundation in a private placement at a purchase price per share equal to $1.14, the average of the daily closing price per share of the Company’s common stock on the NASDAQ Stock Market for the twenty consecutive trading days ending on April 7, 2016, for aggregate proceeds to the Company of approximately $5,000,000 (the “Gates Foundation Investment”). The Securities Purchase Agreement includes customary representations, warranties and covenants of the parties. The closing of the Gates Foundation Investment occurred on May 10, 2016. In connection with the entry into the Securities Purchase Agreement, on April 8, 2016, the Company and the Gates Foundation entered into a Charitable Purposes Letter Agreement, pursuant to which the Company agreed to expend an aggregate amount not less than the amount of the Gates Foundation Investment to develop a yeast strain that produces artemisinic acid and/or amorphadiene at a low cost and to supply such artemisinic acid and amorphadiene to companies qualified to convert artemisinic acid and amorphadiene to artemisinin for inclusion in artemisinin combination therapies used to treat malaria commencing in 2017. If the Company defaults in its obligation to use the proceeds from the Gates Foundation Investment as set forth above or defaults under certain other commitments in the Charitable Purposes Letter Agreement, the Gates Foundation will have the right to request that the Company redeem, or facilitate the purchase by a third party of, the Gates Foundation Investment shares then held by the Gates Foundation at a price per share equal to the greater of (i) the closing price of the Company’s common stock on the trading day prior to the redemption or purchase, as applicable, or (ii) an amount equal to $1.14 plus a compounded annual return of 10%. The funding received is classified as mezzanine equity. 2016 Convertible Note Offering See Note 5, “Debt” for details regarding the 2016 Convertible Note Offering. February and June 2016 Private Placements See Note 5, “Debt” for details regarding the February and June 2016 Private Placements. At Market Issuance Sales Agreement On March 8, 2016, the Company entered into an At Market Issuance Sales Agreement (the “ATM Sales Agreement”) with FBR Capital Markets & Co. and MLV & Co. LLC (the “Agents”) under which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $50.0 million (the “ATM Shares”) from time to time through the Agents, acting as its sales agents, under the Company’s Registration Statement on Form S-3 (File No. 333-203216), effective April 15, 2015. Sales of the ATM Shares through the Agents, if any, will be made by any method that is deemed an “at the market offering” as defined in Rule 415 under the Securities Act, including by means of ordinary brokers’ transactions at market prices, in block transactions, or as otherwise agreed by the Company and the Agents. Each time that the Company wishes to issue and sell ATM Shares under the ATM Sales Agreement, the Company will notify one of the Agents of the number of ATM Shares to be issued, the dates on which such sales are anticipated to be made, any minimum price below which sales may not be made and other sales parameters as the Company deems appropriate. The Company will pay the designated Agent a commission rate of up to 3.0% of the gross proceeds from the sale of any ATM Shares sold through such Agent as agent under the ATM Sales Agreement. The ATM Sales Agreement contains customary terms, provisions, representations and warranties. The ATM Sales Agreement includes no commitment by other parties to purchase shares the Company offers for sale. During the nine months ended September 30, 2016, the Company did not sell any shares of common stock under the ATM Sales Agreement. As of the date hereof, $50.0 million remained available for future sales under the ATM Sales Agreement.

XML 32 R16.htm IDEA: XBRL DOCUMENT

Note 9 - Goodwill and Intangible Assets

9 Months Ended

Sep. 30, 2016

Goodwill and Intangible Assets Disclosure [Text Block]

9. Goodwill and Intangible Assets

The following table presents the components of the Company's intangible assets (in thousands):

			September 30, 2016							December 31, 2015
	Useful Life in Years		Gross Carrying Amount		Accumulated Amortization/ Impairment			Net Carrying Value		Gross Carrying Amount		Accumulated Amortization/ Impairment			Net Carrying Value
In-process research and development		Indefinite	$	8,560	$	(8,560	)	$	—	$	8,560	$	(8,560	)	$	—
Acquired licenses and permits		2		772		(772	)		—		772		(772	)		—
Goodwill		Indefinite		560		—			560		560		—			560
			$	9,892	$	(9,332	)	$	560	$	9,892	$	(9,332	)	$	560

The Company has a single reportable segment (see Note 15, “Reporting Segments” for further details). Consequently, all of the Company's goodwill is attributable to that single reportable segment.

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

XML 33 R17.htm IDEA: XBRL DOCUMENT

Note 10 - Stockholders' Deficit	9 Months Ended
Note 10 - Stockholders' Deficit	Sep. 30, 2016
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10. Stockholders’ Deficit Unexercised Common Stock Warrants As of September 30, 2016 and 2015, the Company had 14,663,411 and 50,699,368, respectively, of unexercised common stock warrants with exercise prices ranging from $0.01 to $10.67 per warrant and a weighted average remaining maturity of 5.9 years.

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

XML 34 R18.htm IDEA: XBRL DOCUMENT

Note 11 - Stock-based Compensation

9 Months Ended

Sep. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

11. Stock-Based Compensation

The Company’s stock option activity and related information for the nine months ended September 30, 2016 was as follows:

	Number Outstanding			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
								(in thousands)
Outstanding - December 31, 2015		12,930,112		$	4.77		7.39	$	22
Options granted		3,324,775		$	0.58		—		—
Options exercised		(134	)	$	0.28		—		—
Options cancelled		(2,393,835	)	$	5.59		—		—
Outstanding - September 30, 2016		13,860,918		$	3.62		7.27	$	—
Vested and expected to vest after September 30, 2016		12,598,270		$	3.86		7.08	$	—
Exercisable at September 30, 2016		6,788,182		$	5.84		5.47	$	—

The Company’s restricted stock units (or "RSUs") and restricted stock activity and related information for the nine months ended September 30, 2016 was as follows:

	RSUs			Weighted- Average Grant- Date Fair Value		Weighted Average Remaining Contractual Life (Years)
Outstanding - December 31, 2015		5,554,844		$	2.03		1.61
Awarded		4,374,389		$	0.60		—
Vested		(1,467,569	)	$	2.19		—
Forfeited		(987,109	)	$	1.49		—
Outstanding - September 30, 2016		7,474,555		$	1.23		1.52
Expected to vest after September 30, 2016		5,898,952		$	2.72		1.39

The following table summarizes information about stock options outstanding as of September 30, 2016:

			Options Outstanding						Options Exercisable
Exercise Price			Number of Options		Weighted- Average Remaining Contractual Life (Years)		Weighted-Average Exercise Price		Number of Options		Weighted-Average Exercise Price
$0.28	—	$0.57		372,754		9.71	$	0.43		3,254	$	0.28
$0.59	—	$0.59		2,574,375		9.62	$	0.59		—	$	—
$0.81	—	$1.73		2,063,938		8.94	$	1.64		166,987	$	1.61
$1.75	—	$1.96		1,546,638		8.48	$	1.91		536,904	$	1.90
$1.98	—	$2.81		1,393,357		6.43	$	2.61		1,079,929	$	2.66
$2.85	—	$3.44		1,369,225		6.49	$	3.02		1,137,340	$	3.01
$3.51	—	$3.51		1,577,760		7.33	$	3.51		970,489	$	3.51
$3.55	—	$4.31		1,761,134		3.86	$	3.97		1,691,542	$	3.98
$4.35	—	$26.84		1,141,737		3.94	$	17.59		1,141,737	$	17.59
$30.17	—	$30.17		60,000		4.45	$	30.17		60,000	$	30.17
$0.28	—	$30.17		13,860,918		7.27	$	3.62		6,788,182	$	5.84

Stock-Based Compensation Expense

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Research and development	$	481	$	530	$	1,457	$	1,776
Sales, general and administrative		1,327		1,726		4,191		5,188
Total stock-based compensation expense	$	1,808	$	2,256	$	5,648	$	6,964

	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Expected dividend yield		—	%		—	%		—	%		—	%
Risk-free interest rate		1.2	%		2	%		1.32	%		2	%
Expected term (in years)		6.16			6.03			6.23			6.00
Expected volatility		76.7	%		74	%		73	%		74	%

Expected Dividend Yield

—The Company has never paid dividends and does not expect to pay dividends.

Risk-Free Interest Rate

—The risk-free interest rate was based on the market yield currently available on United States Treasury securities with maturities approximately equal to the option’s expected term.

Expected Term

—Expected term represents the period that the Company’s stock-based awards are expected to be outstanding. The Company’s assumptions about the expected term have been based on that of companies that have similar industry, life cycle, revenue, and market capitalization and the historical data on employee exercises.

Expected Volatility

—The expected volatility is based on a combination of historical volatility for the Company's stock and the historical stock volatilities of several of the Company’s publicly listed comparable companies over a period equal to the expected terms of the options, as the Company does not have a long trading history.

Forfeiture Rate

—The Company estimates its forfeiture rate based on an analysis of its actual forfeitures and will continue to evaluate the adequacy of the forfeiture rate based on actual forfeiture experience, analysis of employee turnover behavior, and other factors. The impact from a forfeiture rate adjustment will be recognized in full in the period of adjustment, and if the actual number of future forfeitures differs from that estimated by the Company, the Company may be required to record adjustments to stock-based compensation expense in future periods.

Each of the inputs discussed above is subjective and generally requires significant management and director judgment.

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

XML 35 R19.htm IDEA: XBRL DOCUMENT

Note 12 - Employee Benefit Plan	9 Months Ended
Note 12 - Employee Benefit Plan	Sep. 30, 2016
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	12. Employee Benefit Plan The Company established a 401(k) Plan to provide tax deferred salary deductions for all eligible employees. Participants may make voluntary contributions to the 401(k) Plan up to 90% of their eligible compensation, limited by certain Internal Revenue Service (or the "IRS") restrictions. Effective January 2014, the Company implemented a discretionary employer match plan whereby the Company will match employee contributions up to the IRS limit or 90% of compensation, with a minimum one year of service required for vesting. The total matching amount for each of the three months ended September 30, 2016 and 2015 was $0.1 million and $0.1 million, respectively, and $0.3 million and $0.4 million for the nine months ended September 30, 2016 and 2015, respectively.

XML 36 R20.htm IDEA: XBRL DOCUMENT

Note 13 - Related Party Transactions	9 Months Ended
Note 13 - Related Party Transactions	Sep. 30, 2016
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	13. Related Party Transactions Related Party Financings See Note 5, “Debt” for a description of the June 2016 Private Placement transaction with Foris Ventures, LLC, a related party of the Company, the February 2016 Private Placement transaction with Foris Ventures, LLC, Naxyris S.A. and Biolding SA, each a related party of the Company, and the March 2016 R&D Note transaction with Total. In addition, see Note 18, “Subsequent Events” for descriptions of additional related party financings subsequent to September 30, 2016. As of September 30, 2016 and December 31, 2015, convertible notes and loans with related parties were outstanding in aggregate amount of $63.5 million and $43.0 million, respectively, net of debt discount and issuance costs of $2.6 million and $1.9 million, respectively. The fair value of the derivative liability related to the related party convertible notes as of September 30, 2016 and December 31, 2015 was $1.9 million and $7.9 million, respectively. The Company recognized a loss from change in fair value of the derivative instruments of $0.6 million and $12.4 million for the three months ended September 30, 2016 and September 2015, respectively, and a gain from change in fair value of the derivative instruments of $7.7 million for the nine months ended September 30, 2016 and a loss from change in fair value of the derivative instruments of $0.7 million for the nine months ended September 30, 2015, respectively (see Note 3, "Fair Value of Financial Instruments" for further details). Related Party Revenues The Company recognized related party revenues from product sales to Total of zero and $2,000 for the three months ended September 30, 2016 and 2015, respectively, and zero and $2,000 for the nine months ended September 30, 2016 and 2015, respectively. Related party accounts receivable from Total as of September 30, 2016 and December 31, 2015, were $0.7 million and $1.2 million, respectively. The Company recognized related party revenues from product sales to Novvi of $1.4 million and zero for the three months ended September 30, 2016 and 2015, respectively, and $1.4 million and zero for the nine months ended September 30, 2016 and 2015, respectively. Related party accounts receivable from Novvi as of September 30, 2016 and December 31, 2015, were $0.0 million and $0.5 million, respectively. Loans to Related Parties See Note 7, "Joint Ventures and Noncontrolling Interest" for details of the Company's transactions with its affiliate, Novvi LLC. Joint Venture with Total In November 2013, the Company and Total formed TAB as discussed above under Note 7, "Joint Ventures and Noncontrolling Interest." Pilot Plant Agreements In May 2014, the Company received the final consents necessary for a Pilot Plant Services Agreement (or the “Pilot Plant Services Agreement”) and a Sublease Agreement (or the “Sublease Agreement”), each dated as of April 4, 2014 (collectively the “Pilot Plant Agreements”), between the Company and Total. The Pilot Plant Agreements generally have a term of five years. Under the terms of the Pilot Plant Services Agreement, the Company agreed to provide certain fermentation and downstream separations scale-up services and training to Total in exchange for an aggregate annual fee payable by Total for all services in the amount of up to approximately $0.9 million per annum. In July 2015, Total and the Company entered into Amendment #1 to the Pilot Plant Services Agreement (or the "Pilot Plant Agreement Amendment"), whereby the Company agreed to waive a portion of these fees, up to approximately $2.0 million, over the term of the Pilot Plant Services Agreement in connection with the restructuring of TAB discussed above in Note 7, "Joint Ventures and Non-controlling Interest." Under the Sublease Agreement, the Company receives an annual base rent payable by Total of approximately $0.1 million per annum. As of September 30, 2016, the Company had received $1.7 million in cash under the Pilot Plant Agreements from Total. In connection with these arrangements, sublease payments and service fees of $0.1 million and $0.3 million for the three months ended September 30, 2016 and 2015, respectively, and $0.3 million and $0.8 million for the nine months ended September 30, 2016 and 2015, respectively, were offset against costs and operating expenses.

XML 37 R21.htm IDEA: XBRL DOCUMENT

Note 14 - Income Taxes	9 Months Ended
Note 14 - Income Taxes	Sep. 30, 2016
Notes to Financial Statements
Income Tax Disclosure [Text Block]	14. Income Taxes The Company recorded a provision for income taxes of $0.1 million for each of the three months ended September 30, 2016 and 2015, and $0.4 million for each of the nine months ended September 30, 2016 and 2015. The provision for income taxes for the nine months ended September 30, 2016 and 2015 consisted of an accrual of Brazilian withholding tax on interest on inter-company loans. Other than the above mentioned provision for income tax, no additional provision for income taxes has been made, net of the valuation allowance, due to cumulative losses since the commencement of the Company's operations. On December 15, 2011, the IRS completed its audit of the Company for tax year 2008 which concluded that there were no adjustments resulting from the audit. While the statutes are closed for tax year 2008, the US federal tax carryforwards (net operating losses and tax credits) may be adjusted by the IRS in the year in which the carryforward is utilized.

XML 38 R22.htm IDEA: XBRL DOCUMENT

Note 15 - Reporting Segments

9 Months Ended

Sep. 30, 2016

Segment Reporting Disclosure [Text Block]

15. Reporting Segments

Revenues by geography are based on the location of the customer. The following tables set forth revenue and long-lived assets by geographic area (in thousands):

Revenues

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Europe	$	1,899	$	459	$	10,527	$	2,138
United States		20,461		6,177		27,869		15,550
Asia		4,126		991		6,039		2,769
Brazil		46		964		467		3,850
Other		12		—		52		—
Total	$	26,544	$	8,591	$	44,954	$	24,307

Long-Lived Assets (Property, Plant and Equipment)

	September 30, 2016		December 31, 2015
Brazil	$	47,348	$	41,093
United States		15,489		18,401
Europe		256		303
Total	$	63,093	$	59,797

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

XML 39 R23.htm IDEA: XBRL DOCUMENT

Note 16 - Comprehensive Loss

9 Months Ended

Sep. 30, 2016

Comprehensive Income (Loss) Note [Text Block]

16. Comprehensive Loss

The components of accumulated other comprehensive loss are as follows (in thousands):

	September 30, 2016			December 31, 2015
Foreign currency translation adjustment, net of tax	$	(39,801	)	$	(47,198	)
Total accumulated other comprehensive loss	$	(39,801	)	$	(47,198	)

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

XML 40 R24.htm IDEA: XBRL DOCUMENT

Note 17 - Net Loss Attributable to Common Stockholders and Net Loss Per Share

9 Months Ended

Sep. 30, 2016

Earnings Per Share [Text Block]

17. Net Loss Attributable to Common Stockholders and Net Loss per Share

	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Numerator:
Net loss attributable to Amyris, Inc. common stockholders	$	(19,704	)	$	(76,664	)	$	(48,579	)	$	(176,034	)
Interest on convertible debt		—			—			5,093			—
Accretion of debt discount		—			—			5,304			—
Gain from change in fair value of derivative instruments		—			—			(37,593	)		—
Net loss attributable to Amyris, Inc. common stockholders after assumed conversion	$	(19,704	)	$	(76,664	)	$	(75,775	)	$	(176,034	)

Denominator:
Weighted average shares of common stock outstanding for basic EPS		249,190,339			140,374,297			226,772,159			100,103,007
Basic loss per share	$	(0.08	)	$	(0.55	)	$	(0.21	)	$	(1.76	)

Weighted average shares of common stock outstanding		249,190,339			140,374,297			226,772,159			100,103,007
Effect of dilutive securities:
Convertible promissory notes		—			—			41,602,952			—
Weighted common stock equivalents		—			—			41,602,952			—

Diluted weighted-average common shares		249,190,339			140,374,297			268,375,111			100,103,007
Diluted loss per share	$	(0.08	)	$	(0.55	)	$	(0.28	)	$	(1.76	)

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Period-end stock options to purchase common stock		13,860,918		11,307,679		13,860,918		11,307,679
Convertible promissory notes (1)		66,474,148		43,451,433		23,760,389		43,451,433
Period-end common stock warrants		14,663,411		2,901,926		14,663,411		2,901,926
Period-end restricted stock units		7,474,555		3,558,243		7,474,555		3,558,243
Total		102,473,032		61,219,281		59,759,273		61,219,281

______________

(1)

XML 41 R25.htm IDEA: XBRL DOCUMENT

Note 18 - Subsequent Events	9 Months Ended
Note 18 - Subsequent Events	Sep. 30, 2016
Notes to Financial Statements
Subsequent Events [Text Block]	18. Subsequent Events Senior Secured Loan Facility Amendment On October 6, 2016, in connection with the entry into the Ginkgo Collaboration Agreement, the Company, certain of its subsidiaries and Stegodon, an affiliate of Ginkgo, entered into a fourth amendment of the Senior Secured Loan Facility. Pursuant to the fourth amendment, subject to the Company extending (or the “Extension Condition”) the maturity of the Fidelity Notes, the parties agreed to extend the maturity date of all outstanding loans under the Senior Secured Loan Facility to the business day immediately preceding the earliest maturity of the Fidelity Notes and the outstanding Tranche Notes held by non-affiliates, after giving effect to any extensions thereof at or prior to the satisfaction of the Extension Condition, but in no event later than April 12, 2019. In addition, the parties agreed that the Company would be required to pay only the interest accruing on all outstanding loans under the Senior Secured Loan Facility until the maturity date, provided that the Company would be required to apply certain monies received by the Company under the Ginkgo Collaboration Agreement towards repayment of the outstanding loans under the Senior Secured Loan Facility, up to a maximum amount of $1 million per month. Furthermore, pursuant to the fourth amendment, Stegodon agreed to waive the Minimum Cash Covenant under the Senior Secured Loan Facility until the maturity date. See Note 5, “Debt” for additional details regarding the Senior Secured Loan Facility and Note 8, “Significant Agreements” for additional information regarding the Ginkgo Collaboration Agreement. 2016 Convertible Note Offering On October 13, 2016, the Company issued and sold the $2.0 Million Note under the May 2016 Purchase Agreement to the purchaser, for proceeds to the Company of $2.0 million. Upon the issuance of the $2 Million Note, all 2016 Convertible Notes provided for under the May 2016 Purchase Agreement had been issued and sold. See Note 5, “Debt” for additional information regarding the May 2016 Purchase Agreement and the 2016 Convertible Notes. October 2016 Private Placements On October 21 and October 27, 2016, the Company entered into separate Note Purchase Agreements (or the “October 2016 Purchase Agreements”) with Foris Ventures, LLC and Ginkgo Bioworks, Inc., respectively, for the sale of $6.0 million and $8.5 million, respectively, in aggregate principal amount of secured promissory notes (or the “October 2016 Private Notes”) in exchange for aggregate proceeds to the Company of $6.0 million and $8.5 million, respectively (or the “October 2016 Private Placements”). The October 2016 Private Notes were issued in private placements pursuant to the exemption from registration under Section 4(2) of the Securities Act of 1933, as amended and Regulation D promulgated under the Securities Act. The October 2016 Private Placements closed on October 21 and October 27, 2016, respectively. The October 2016 Private Notes are collateralized by a second priority lien on the assets securing the Company’s obligations under the Senior Secured Loan Facility, and are subordinate to the Company’s obligations under the Senior Secured Loan Facility pursuant to Subordination Agreements, dated as of the respective dates of the October 2016 Purchase Agreements, by and among the Company, the applicable purchaser and the administrative agent under the Company’s Senior Secured Loan Facility. Interest will accrue on the October 2016 Private Notes from and including October 21 and 27, 2016, respectively, at a rate of 13.50% per annum and is payable in full on May 15, 2017, the maturity date of the October 2016 Private Notes, unless the October 2016 Private Notes are prepaid in accordance with their terms prior to such date. The October 2016 Purchase Agreements and the October 2016 Private Notes contain customary terms, provisions, representations and warranties, including certain events of default after which the October 2016 Private Notes may be due and payable immediately, as set forth in the October 2016 Private Notes. Guanfu Credit Agreement On October 26, 2016, the Company and Guanfu Holding Co., Ltd. (or, together with its subsidiaries, “Guanfu”), an existing commercial partner of the Company, entered into a credit agreement (or the “Guanfu Credit Agreement”) to make available to the Company an unsecured credit facility with an aggregate principal amount of up to $25.0 million (or the “Guanfu Credit Facility”), which the Company may borrow from time to time in up to three closings (each such borrowing, a “Guanfu Loan”). Each Guanfu Loan will have a term of five years and will accrue interest at a rate of 10% per annum, payable quarterly. The Company may at its option repay the Guanfu Loans before their maturity date, in whole or in part, at a price equal to 100% of the amount being repaid plus accrued and unpaid interest on such amount to the date of repayment. The Guanfu Credit Agreement contains customary representations, warranties and covenants of the parties, as well as customary provisions regarding, among other things, dispute resolution and governing law. Upon the occurrence of certain specified events of default under the Guanfu Credit Facility, the Company will grant to Guanfu an exclusive, royalty-free, global license to certain intellectual property useful in connection with Guanfu’s existing commercial relationship with the Company. In addition, in the event the Company fails to pay interest or principal under any Guanfu Loan within ten days of when due, the Company will also be required, subject to applicable laws and regulations, to repay the outstanding principal amount under such Guanfu Loan, together with accrued and unpaid interest, in the form of shares of the Company’s common stock at a per share price equal to 90% of the volume weighted average closing sale price of the Company’s common stock for the 90 trading days ending on and including the trading day that is two trading days preceding such default. The effectiveness of the Guanfu Credit Agreement is subject to the parties obtaining certain required approvals, and upon the effective date of the Guanfu Credit Agreement, the Company will grant to Guanfu the global exclusive purchase right with respect to the Company products subject to the parties’ pre-existing commercial relationship. The initial funding of the Guanfu Credit Facility is scheduled to occur on December 1, 2016, subject to Guanfu’s right to extend such initial funding to a date no later than December 31, 2016. Nenter Cooperation Agreement On October 26, 2016, the Company entered into a Cooperation Agreement (or the “Cooperation Agreement”) with Nenter & Co., Inc. (or “Nenter”), a subsidiary of Guanfu. Under the Cooperation Agreement, the parties will collaborate to create and develop certain compounds and, in the event the parties achieve certain specified development targets, the parties would establish and implement a worldwide manufacturing and commercialization plan (or the “Commercialization Plan”) relating thereto. The term of the Cooperation Agreement will be two years from the effectiveness of the Cooperation Agreement (or five years in the event the parties pursue the Commercialization Plan), which will occur upon the parties obtaining certain required approvals, subject to the rights of the parties to terminate the Cooperation Agreement upon a material breach by the other party or the failure to obtain certain governmental approvals or authorizations, as provided in the Cooperation Agreement. The Cooperation Agreement also contains customary representations, warranties and covenants of the parties, as well as customary terms and provisions regarding, among other things, indemnification, dispute resolution, confidentiality and governing law. In addition, pursuant to the terms of, and as consideration for, the Cooperation Agreement, promptly after the effectiveness of the Cooperation Agreement, the Company will issue to Nenter a warrant to purchase 10 million shares of the Company’s common stock at an exercise price of $0.50 per share, exercisable on or before December 31, 2016. The warrant will be issued pursuant to the exemption from registration under Section 4(2) of the Securities Act and Regulation D promulgated under the Securities Act. Furthermore, pursuant to the terms of the warrant, upon the request of Nenter, the Company will use its best efforts to cause the shares of common stock issued upon exercise of the warrant to be registered under the Securities Act within 90 days of the exercise of the warrant.

XML 42 R26.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying interim condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (or “GAAP”) and with the instructions for Form 10-Q and Regulation S-X. Accordingly, they do not include all of the information and notes required for complete financial statements. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Form 10-K for the fiscal year ended December 31, 2015 as filed with the Securities and Exchange Commission (or the “SEC”) on March 30, 2016. The unaudited condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The Company uses the equity method to account for investments in companies, if its investments provide it with the ability to exercise significant influence over operating and financial policies of the investee. Consolidated net income or loss includes the Company’s proportionate share of the net income or loss of these companies. Judgments made by the Company regarding the level of influence over each equity method investment include considering key factors such as the Company’s ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The condensed consolidated financial statements of the Company include the accounts of Amyris, Inc., its subsidiaries and two consolidated variable interest entities (or “VIEs”), with respect to which the Company is considered the primary beneficiary, after elimination of intercompany accounts and transactions. Disclosure regarding the Company’s participation in the VIEs is included in Note 7, "Joint Ventures and Noncontrolling Interest."
Consolidation, Variable Interest Entity, Policy [Policy Text Block]	Variable Interest Entities The Company has interests in joint venture entities that are VIEs. Determining whether to consolidate a VIE requires judgment in assessing (i) whether an entity is a VIE and (ii) if the Company is the entity’s primary beneficiary and thus required to consolidate the entity. To determine if the Company is the primary beneficiary of a VIE, the Company evaluates whether it has (i) the power to direct the activities that most significantly impact the VIE’s economic performance and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. The Company’s evaluation includes identification of significant activities and an assessment of its ability to direct those activities based on governance provisions and arrangements to provide or receive product and process technology, product supply, operations services, equity funding and financing and other applicable agreements and circumstances. The Company’s assessment of whether it is the primary beneficiary of its VIEs requires significant assumptions and judgment.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates In preparing the unaudited condensed consolidated financial statements, management must make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Unaudited Interim Financial Information Policy [Policy Text Block]	Unaudited Interim Financial Information The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements, except for the impact of adoption of certain accounting standards as described below, and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. In the quarter ended March 31, 2016 the Company adopted Accounting Standards Update (“ASU”) No. 2015-01, Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items, ASU No. 2015-02, Consolidation (Topic 810), ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs , ASU 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40) and ASU No. 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements . Refer to Note 5. "Debt" for the impact of adoption of ASU No. 2015-03 on the Company's condensed consolidated financial statements. None of the other ASU’s adopted had a material impact on the Company’s condensed consolidated financial statements. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In October 2016, the Financial Accounting Standards Board (or “FASB”) issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory on simplifying the accounting for income taxes related to intra-entity asset transfers. The new guidance allows an entity to recognize the tax expense from the sale of an asset in the seller’s tax jurisdiction when the transfers occurs, even though the pre-tax effects of that transaction are eliminated in consolidation. This guidance will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted only in the first quarter of 2017. The Company is evaluating the impact of adopting this new accounting standard update on the financial statements and related disclosures. In August 2016, the FASB issued ASU 2016-15 Classification of Certain Cash Receipts and Cash Payments on the statement of cash flows. The new guidance clarifies classification of certain cash receipts and cash payments in the statement of cash flows. This guidance will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017 and interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the impact of adopting this new accounting standard update on the financial statements and related disclosures. In June 2016, the Financial Accounting Standards Board (or “FASB”) issued ASU No. 2016-13, Allowance for Loan and Lease Losses (Financial Instruments - Credit Losses Topic 326.) . New impairment guidance for certain financial instruments (including trade receivables) will replace the current “incurred loss” model for estimating credit losses with a forward looking “expected loss” model. The ASU is effective for the Company for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early application is permitted as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is evaluating the impact of this standard on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting . This ASU identifies areas for simplification involving several aspects of accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur, as well as certain classifications on the statement of cash flows. This ASU will be effective for fiscal years beginning after December 15, 2016, and interim periods within those annual periods. The Company is currently assessing the potential impact of this ASU on its consolidated financial statements. Early adoption is permitted. The Company is currently assessing the potential impact of this ASU on its consolidated financial statements. Early adoption is permitted. In March 2016, the FASB issued ASU No. 2016-06, Contingent Put and Call Options in Debt Instruments . The amendments in this ASU clarify the requirements for assessing whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts. An entity performing the assessment under the amendments in this ASU is required to assess the embedded call (put) options solely in accordance with the four-step decision sequence. The ASU is effective for financial statements issued for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently assessing the potential impact of this ASU on its financial statements. In February 2016, the FASB issued Accounting Standards Update (or “ASU”) 2016-02- Leases with fundamental changes to how entities account for leases. Lessees will need to recognize a right-of-use asset and a lease liability for virtually all of their leases (other than leases that meet the definition of a short-term lease). The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for initial direct costs. Additional disclosures for leases will also be required. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. The new standard may materially impact the Company’s financial statements. In January 2016, the FASB issued ASU 2016-01 Financial Instruments-Overall , which address certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The amendments in this Update are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Earlier application is permitted under specific circumstances. The Company is currently assessing the potential impact of this standard on its consolidated financial statements. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory , which requires that inventory within the scope of the guidance be measured at the lower of cost and net realizable value. The new standard is being issued as part of the simplification initiative. Prior to the issuance of the standard, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin). The new guidance will be effective for fiscal years beginning after December 15, 2016, including interim periods within those years. Prospective application is required and early adoption is permitted. The Company is currently assessing the impact of adopting this new accounting standard on its financial statements. In August 2014, the FASB issued new guidance related to the disclosure around going concern. The new standard provides guidance around management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosure if substantial doubt exists. The new standard is effective for annual periods ending after December 15, 2016 and for annual periods and interim periods thereafter. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company's financial statements. In May 2014, the FASB issued new guidance related to revenue recognition. In March, April and May 2016, the FASB issued additional amendments to the new revenue guidance relating to reporting revenue on a gross versus net basis, identifying performance obligations, licensing arrangements, collectability, noncash consideration, presentation of sales tax, and transition. This new standard will replace all current GAAP guidance on this topic and eliminate all industry-specific guidance. The new revenue recognition update guidance provides a unified model to determine how revenue is recognized. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The FASB has issued several updates to the standard which i) clarify the application of the principal versus agent guidance (ASU 2016-08); ii) clarify the guidance on inconsequential and perfunctory promises and licensing (ASU 2016-10) and iii) narrow-scope improvements and practical expedients (ASU 2016-12). On July 9, 2015, the FASB voted to defer the effective date by one year to December 15, 2017 for interim and annual reporting periods beginning after that date and permitted early adoption of the standard, but not before the original effective date of December 15, 2016. Entities have the option of using either a full retrospective or a modified retrospective approach to adopt the new standard. Therefore, the new standard will be effective commencing with our quarter ending March 31, 2018. The Company is currently assessing the potential impact of this new standard on its consolidated financial statements and has not selected the transition method.

XML 43 R27.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value of Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2016

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Level 1		Level 2		Level 3		Balance as of September 30, 2016
Financial Assets
Money market funds	$	59	$	—	$	—	$	59
Certificates of deposit		1,713		—		—		1,713
Total financial assets	$	1,772	$	—	$	—	$	1,772
Financial Liabilities
Loans payable (1)	$	—	$	34,146	$	—	$	34,146
Credit facilities (1)		—		19,310		—		19,310
Convertible notes (1)		—		—		109,885		109,885
Compound embedded derivative liabilities		—		—		3,827		3,827
Currency interest rate swap derivative liability		—		3,471		—		3,471
Total financial liabilities	$	—	$	56,927	$	113,712	$	170,639

	Level 1		Level 2		Level 3		Balance as of December 31, 2015
Financial Assets
Money market funds	$	2,078	$	—	$	—	$	2,078
Certificates of deposit		1,520		—		—		1,520
Total financial assets	$	3,598	$	—	$	—	$	3,598
Financial Liabilities
Loans payable (1)	$	—	$	9,541	$	—	$	9,541
Credit facilities (1)		—		34,893		—		34,893
Convertible notes (1)		—		—		96,291		96,291
Compound embedded derivative liabilities		—		—		46,430		46,430
Currency interest rate swap derivative liability		—		5,009		—		5,009
Total financial liabilities	$	—	$	49,443	$	142,721	$	192,164

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	2016
Balance at January 1	$	96,291
Additions of convertible notes		13,000
Conversion/extinguishment of convertible notes		(21,579	)
Change in fair value of convertible notes		22,173
Balance at September 30	$	109,885

Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	2016
Balance at January 1	$	46,430
Derecognition on conversion/extinguishment		(2,734	)
Gain from change in fair value of derivative liabilities		(39,869	)
Balance at September 30	$	3,827

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]

	September 30, 2016			September 30, 2015
Risk-free interest rate	0.20%	-	0.84%	0.93%	-	1.07%
Risk-adjusted yields	17.30%	-	27.43%	24.40%	-	39.90%
Stock-price volatility		45%			45%
Probability of change in control		5%			5%
Stock price		$0.58			$2.01
Credit spread	16.49%	-	26.60%	28.81%	-	38.83%
Estimated conversion dates	2016	-	2019	2015	-	2019

Derivative Instruments, Gain (Loss) [Table Text Block]

	Income Statement Classification	Three Months Ended September 30,						Nine Months Ended September 30,
Type of Derivative Contract		2016			2015			2016		2015
Currency interest rate swap	Gain (loss) from change in fair value of derivative instruments	$	(145	)	$	(1,796	)	$	1,957	$	(3,201	)

Schedule of Derivative Liabilities at Fair Value [Table Text Block]

	September 30, 2016		December 31, 2015
Fair market value of compound embedded derivative liabilities	$	3,827	$	46,430
Fair value of swap obligations		3,471		5,009
Total derivative liabilities	$	7,298	$	51,439

XML 44 R28.htm IDEA: XBRL DOCUMENT

Note 4 - Balance Sheet Components (Tables)

9 Months Ended

Sep. 30, 2016

Schedule of Inventory, Current [Table Text Block]

	September 30, 2016		December 31, 2015
Raw materials	$	2,664	$	2,204
Work-in-process		1,809		3,583
Finished goods		3,426		5,099
Inventories, net	$	7,899	$	10,886

Property, Plant and Equipment [Table Text Block]

	September 30, 2016			December 31, 2015
Machinery and equipment	$	85,538		$	72,876
Leasehold improvements		38,791			38,519
Computers and software		9,545			9,117
Buildings		4,718			3,922
Furniture and office equipment		2,335			2,234
Vehicles		195			215
Construction in progress		6,430			5,736
		147,552			132,619
Less: accumulated depreciation and amortization		(84,459	)		(72,822	)
Property, plant and equipment, net	$	63,093		$	59,797

Schedule of Other Assets, Noncurrent [Table Text Block]

	September 30, 2016		December 31, 2015
Recoverable taxes from Brazilian government entities	$	11,955	$	8,887
Deposits on property and equipment, including taxes		292		243
Other		1,410		1,227
Total other assets	$	13,657	$	10,357

Schedule of Accrued and Other Current Liabilities [Table Text Block]

	September 30, 2016		December 31, 2015
Withholding tax related to conversion of related party notes	$	4,964	$	4,723
Professional services		5,406		4,017
SMA relocation accrual		4,380		3,641
Accrued interest		8,283		1,984
Tax-related liabilities		2,325		2,505
Accrued vacation		1,932		2,023
Payroll and related expenses		4,268		3,122
Deferred rent, current portion		1,110		1,111
Contractual obligations to contract manufacturers		680		—
Fair value swap short-term		586		—
Other		978		1,142
Total accrued and other current liabilities	$	34,912	$	24,268

XML 45 R29.htm IDEA: XBRL DOCUMENT

Note 5 - Debt and Mezzanine Equity (Tables)

9 Months Ended

Sep. 30, 2016

Schedule of Debt [Table Text Block]

	September 30, 2016			December 31, 2015

Senior secured loan facility	$	28,438		$	31,590
BNDES credit facility		1,471			1,956
FINEP credit facility		777			840
Total credit facilities		30,686			34,386
Convertible notes		68,533			61,233
Related party convertible notes		40,611			42,749
Related party loan payable		22,847			—
Loans payable		12,954			13,606
Total debt		175,631			151,974
Less: current portion		(75,016	)		(36,281	)
Long-term debt	$	100,615		$	115,693
Mezzanine equity (1)		5,000			—

Schedule of Long-term Debt Instruments [Table Text Block]

Years ending December 31:	Related Party Convertible Debt			Convertible Debt			Loans Payable			Related Party Loans payable		Credit Facility			Total
2016 (remaining three months)	$	312		$	3,240		$	1,770		$	844	$	33,234		$	39,400
2017		4,837			23,562			2,870			26,257		1,551			59,077
2018		13,937			17,736			2,450			—		322			34,445
2019		26,080			79,937			2,342			—		78			108,437
2020		—			—			2,234			—		—			2,234
Thereafter		—			—			3,314			—		—			3,314
Total future minimum payments		45,166			124,475			14,980			27,101		35,185			246,907
Less: amount representing interest (1)		(4,555	)		(55,942	)		(2,026	)		(4,254		(4,499	)		(71,276	)
Present value of minimum debt payments		40,611			68,533			12,954			22,847		30,686			175,631
Less: current portion present value of minimum debt payments		(3,611	)		(15,357	)		(3,275	)		(22,847		(29,926	)		(75,016	)
Noncurrent portion of debt	$	37,000		$	53,176		$	9,679		$	—	$	760		$	100,615

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

XML 46 R30.htm IDEA: XBRL DOCUMENT

Note 6 - Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2016

Schedule Of Future Minimum Payments For Lease Obligations [Table Text Block]

Years ending December 31:	Capital Leases			Operating Leases		Total Lease Obligations
2016 (remaining three months)	$	471		$	1,762	$	2,233
2017		525			6,888		7,413
2018		28			6,890		6,918
2019		—			6,777		6,777
2020		—			7,008		7,008
Thereafter		—			18,210		18,210
Total future minimum lease payments		1,024		$	47,535	$	48,559
Less: amount representing interest		(26	)
Present value of minimum lease payments		998
Less: current portion		(942	)
Long-term portion	$	56

XML 47 R31.htm IDEA: XBRL DOCUMENT

Note 7 - Joint Ventures and Noncontrolling Interests (Tables)

9 Months Ended

Sep. 30, 2016

Schedule of Variable Interest Entities [Table Text Block]

(In thousands)	September 30, 2016		December 31, 2015
Assets	$	493	$	6,993
Liabilities	$	257	$	1,221

Noncontrolling Interest [Table Text Block]

	2016			2015
Balance at January 1	$	391		$	611
Foreign currency translation adjustment		—			(393	)
Income attributable to noncontrolling interest		—			78
Acquisition of noncontrolling interest		(277	)		—
Balance at September 30	$	114		$	296

Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.

XML 48 R32.htm IDEA: XBRL DOCUMENT

Note 9 - Goodwill and Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2016

Schedule of Intangible Assets and Goodwill [Table Text Block]

			September 30, 2016							December 31, 2015
	Useful Life in Years		Gross Carrying Amount		Accumulated Amortization/ Impairment			Net Carrying Value		Gross Carrying Amount		Accumulated Amortization/ Impairment			Net Carrying Value
In-process research and development		Indefinite	$	8,560	$	(8,560	)	$	—	$	8,560	$	(8,560	)	$	—
Acquired licenses and permits		2		772		(772	)		—		772		(772	)		—
Goodwill		Indefinite		560		—			560		560		—			560
			$	9,892	$	(9,332	)	$	560	$	9,892	$	(9,332	)	$	560

XML 49 R33.htm IDEA: XBRL DOCUMENT

Note 11 - Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2016

Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity [Table Text Block]

	Number Outstanding			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
								(in thousands)
Outstanding - December 31, 2015		12,930,112		$	4.77		7.39	$	22
Options granted		3,324,775		$	0.58		—		—
Options exercised		(134	)	$	0.28		—		—
Options cancelled		(2,393,835	)	$	5.59		—		—
Outstanding - September 30, 2016		13,860,918		$	3.62		7.27	$	—
Vested and expected to vest after September 30, 2016		12,598,270		$	3.86		7.08	$	—
Exercisable at September 30, 2016		6,788,182		$	5.84		5.47	$	—

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]

	RSUs			Weighted- Average Grant- Date Fair Value		Weighted Average Remaining Contractual Life (Years)
Outstanding - December 31, 2015		5,554,844		$	2.03		1.61
Awarded		4,374,389		$	0.60		—
Vested		(1,467,569	)	$	2.19		—
Forfeited		(987,109	)	$	1.49		—
Outstanding - September 30, 2016		7,474,555		$	1.23		1.52
Expected to vest after September 30, 2016		5,898,952		$	2.72		1.39

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]

			Options Outstanding						Options Exercisable
Exercise Price			Number of Options		Weighted- Average Remaining Contractual Life (Years)		Weighted-Average Exercise Price		Number of Options		Weighted-Average Exercise Price
$0.28	—	$0.57		372,754		9.71	$	0.43		3,254	$	0.28
$0.59	—	$0.59		2,574,375		9.62	$	0.59		—	$	—
$0.81	—	$1.73		2,063,938		8.94	$	1.64		166,987	$	1.61
$1.75	—	$1.96		1,546,638		8.48	$	1.91		536,904	$	1.90
$1.98	—	$2.81		1,393,357		6.43	$	2.61		1,079,929	$	2.66
$2.85	—	$3.44		1,369,225		6.49	$	3.02		1,137,340	$	3.01
$3.51	—	$3.51		1,577,760		7.33	$	3.51		970,489	$	3.51
$3.55	—	$4.31		1,761,134		3.86	$	3.97		1,691,542	$	3.98
$4.35	—	$26.84		1,141,737		3.94	$	17.59		1,141,737	$	17.59
$30.17	—	$30.17		60,000		4.45	$	30.17		60,000	$	30.17
$0.28	—	$30.17		13,860,918		7.27	$	3.62		6,788,182	$	5.84

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Research and development	$	481	$	530	$	1,457	$	1,776
Sales, general and administrative		1,327		1,726		4,191		5,188
Total stock-based compensation expense	$	1,808	$	2,256	$	5,648	$	6,964

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Expected dividend yield		—	%		—	%		—	%		—	%
Risk-free interest rate		1.2	%		2	%		1.32	%		2	%
Expected term (in years)		6.16			6.03			6.23			6.00
Expected volatility		76.7	%		74	%		73	%		74	%

XML 50 R34.htm IDEA: XBRL DOCUMENT

Note 15 - Reporting Segments (Tables)

9 Months Ended

Sep. 30, 2016

Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Europe	$	1,899	$	459	$	10,527	$	2,138
United States		20,461		6,177		27,869		15,550
Asia		4,126		991		6,039		2,769
Brazil		46		964		467		3,850
Other		12		—		52		—
Total	$	26,544	$	8,591	$	44,954	$	24,307

Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]

	September 30, 2016		December 31, 2015
Brazil	$	47,348	$	41,093
United States		15,489		18,401
Europe		256		303
Total	$	63,093	$	59,797

XML 51 R35.htm IDEA: XBRL DOCUMENT

Note 16 - Comprehensive Loss (Tables)

9 Months Ended

Sep. 30, 2016

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

	September 30, 2016			December 31, 2015
Foreign currency translation adjustment, net of tax	$	(39,801	)	$	(47,198	)
Total accumulated other comprehensive loss	$	(39,801	)	$	(47,198	)

XML 52 R36.htm IDEA: XBRL DOCUMENT

Note 17 - Net Loss Attributable to Common Stockholders and Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2016

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Numerator:
Net loss attributable to Amyris, Inc. common stockholders	$	(19,704	)	$	(76,664	)	$	(48,579	)	$	(176,034	)
Interest on convertible debt		—			—			5,093			—
Accretion of debt discount		—			—			5,304			—
Gain from change in fair value of derivative instruments		—			—			(37,593	)		—
Net loss attributable to Amyris, Inc. common stockholders after assumed conversion	$	(19,704	)	$	(76,664	)	$	(75,775	)	$	(176,034	)

Denominator:
Weighted average shares of common stock outstanding for basic EPS		249,190,339			140,374,297			226,772,159			100,103,007
Basic loss per share	$	(0.08	)	$	(0.55	)	$	(0.21	)	$	(1.76	)

Weighted average shares of common stock outstanding		249,190,339			140,374,297			226,772,159			100,103,007
Effect of dilutive securities:
Convertible promissory notes		—			—			41,602,952			—
Weighted common stock equivalents		—			—			41,602,952			—

Diluted weighted-average common shares		249,190,339			140,374,297			268,375,111			100,103,007
Diluted loss per share	$	(0.08	)	$	(0.55	)	$	(0.28	)	$	(1.76	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Period-end stock options to purchase common stock		13,860,918		11,307,679		13,860,918		11,307,679
Convertible promissory notes (1)		66,474,148		43,451,433		23,760,389		43,451,433
Period-end common stock warrants		14,663,411		2,901,926		14,663,411		2,901,926
Period-end restricted stock units		7,474,555		3,558,243		7,474,555		3,558,243
Total		102,473,032		61,219,281		59,759,273		61,219,281

XML 53 R37.htm IDEA: XBRL DOCUMENT

Note 1 - The Company (Details Textual) $ in Thousands	9 Months Ended
Note 1 - The Company (Details Textual) $ in Thousands	Sep. 30, 2016 USD ($)	Dec. 31, 2015 USD ($)
Number of Operating Segments	2
Working Capital	$ (110,600)
Retained Earnings (Accumulated Deficit)	(1,085,683)	$ (1,037,104)
Cash, Cash Equivalents, and Short-term Investments	2,300
Debt Instrument, Unamortized Discount	36,100
Long-term Debt	175,631	151,974
Long-term Debt, Current Maturities, Including Due to Related Parties	75,016	$ 36,281
Interest Payable	$ 16,200
Percentage of Outstanding Principle to be Maintained in Unencumbered Cash	50.00%

Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.

Fair Value, Inputs, Level 1 [Member]

XML 54 R38.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Details Textual)	9 Months Ended
	Sep. 30, 2016
Variable Interest Entity, Number of Entities	2

XML 55 R39.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value of Financial Instruments (Details Textual) $ in Thousands, BRL in Millions	Sep. 30, 2016 USD ($)	Sep. 30, 2016 BRL	Dec. 31, 2015 USD ($)
Derivative Liabilities [Member] \| Fair Value, Inputs, Level 3 [Member] \| Derivative Liability, Compound Embedded Derivatives [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	$ 3,800		$ 46,400
Fair Value, Inputs, Level 3 [Member] \| Derivative Liability, Compound Embedded Derivatives [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	3,827		$ 46,430
Banco Pine July 2012 Loan Agreement [Member] \| Interest Rate Swap [Member]
Derivative, Notional Amount	$ 6,800	BRL 22
Derivative, Fixed Interest Rate	3.94%	3.94%

XML 56 R40.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value of Financial Instruments - Fair Value, Assets, and Liabilities Measured on Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)
$ in Thousands

Sep. 30, 2016

Dec. 31, 2015

$ 59

$ 2,078

1,713

1,520

1,772

3,598

^[1]

^[2]

^[1]

^[2]

^[1]

^[2]

Fair Value, Inputs, Level 2 [Member]

34,146

^[1]

9,541

^[2]

19,310

^[1]

34,893

^[2]

^[1]

^[2]

3,471

5,009

Fair Value, Inputs, Level 3 [Member]

56,927

49,443

^[1]

^[2]

^[1]

^[2]

109,885

^[1]

96,291

^[2]

3,827

46,430

113,712

142,721

2,078

1,713

1,520

1,772

3,598

34,146

^[1]

9,541

^[2]

19,310

^[1]

34,893

^[2]

109,885

^[1]

96,291

^[2]

3,827

46,430

3,471

5,009

Senior Secured Loan Facility [Member]

$ 170,639

$ 192,164

[1]	These liabilities are carried on the condensed consolidated balance sheet on a historical cost basis.
[2]	These liabilities are carried on the consolidated balance sheet on a historical cost basis (noting that the Remaining Notes subject to the Maturity Treatment Agreement were revalued to fair value on July 29, 2015, see Note 5 "Debt" for details).

XML 57 R41.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value of Financial Instruments - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - Fair Value, Inputs, Level 3 [Member] - Convertible Debt [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2016 USD ($)
Balance, convertible notes	$ 96,291
Additions of convertible notes	13,000
Conversion/extinguishment of convertible notes	(21,579)
Change in fair value of convertible notes	22,173
Balance at September 30	$ 109,885

XML 58 R42.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value of Financial Instruments - Reconciliation for Compound Embedded Derivative Liability (Details) - Fair Value, Inputs, Level 3 [Member] - Derivative Liability, Compound Embedded Derivatives [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2016 USD ($)
Balance, convertible notes	$ 46,430
Derecognition on conversion/extinguishment	(2,734)
Gain from change in fair value of derivative liabilities	(39,869)
Balance at September 30	$ 3,827

XML 59 R43.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value of Financial Instruments - Market-based Assumption and Estimates for Compound Embedded Derivative Liabilities Valuation (Details) - $ / shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Minimum [Member]
Risk-free interest rate	0.20%	0.93%
Risk-adjusted yields	17.30%	24.40%
Credit spread	16.49%	28.81%
Estimated conversion dates	2016	2015
Maximum [Member]
Risk-free interest rate	0.84%	1.07%
Risk-adjusted yields	27.43%	39.90%
Credit spread	26.60%	38.83%
Estimated conversion dates	2019	2019
Expected volatility	45.00%	45.00%
Probability of change in control	5.00%	5.00%
Stock price (in dollars per share)	$ 0.58	$ 2.01

XML 60 R44.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value of Financial Instruments - Derivative Instruments Classification (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Currency Interest Rate Swap [Member] \| Not Designated as Hedging Instrument [Member] \| Gain (Loss) From Change in Fair Value of Derivative Instruments [Member]
Currency interest rate swap	$ (145)	$ (1,796)	$ 1,957	$ (3,201)

XML 61 R45.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value of Financial Instruments - Derivative Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Fair market value of compound embedded derivative liabilities	$ 3,827	$ 46,430
Fair value of swap obligations	3,471	5,009
Total derivative liabilities	$ 7,298	$ 51,439

XML 62 R46.htm IDEA: XBRL DOCUMENT

Note 4 - Balance Sheet Components (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Capital Lease Obligations [Member] \| Machinery and Equipment, Furniture and Office Equipment Under Capital Lease [Member]
Property, Plant and Equipment, Gross	$ 2,300		$ 2,300		$ 2,700
Capital Lease Obligations [Member]
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	400		400		500
Property, Plant and Equipment, Including Capital Leases [Member]
Depreciation, Depletion and Amortization	2,900	$ 3,100	8,600	$ 9,900
Property, Plant and Equipment, Gross	147,552		147,552		132,619
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 84,459		84,459		$ 72,822
Depreciation, Depletion and Amortization			$ 8,561	$ 9,931

XML 63 R47.htm IDEA: XBRL DOCUMENT

Note 4 - Balance Sheet Components - Inventory, Current (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Raw materials	$ 2,664	$ 2,204
Work-in-process	1,809	3,583
Finished goods	3,426	5,099
Inventories, net	$ 7,899	$ 10,886

XML 64 R48.htm IDEA: XBRL DOCUMENT

Note 4 - Balance Sheet Components - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Machinery and Equipment [Member]
Property, plant and equipment	$ 85,538	$ 72,876
Leasehold Improvements [Member]
Property, plant and equipment	38,791	38,519
Computer Equipment and Software [Member]
Property, plant and equipment	9,545	9,117
Building [Member]
Property, plant and equipment	4,718	3,922
Furniture and Fixtures [Member]
Property, plant and equipment	2,335	2,234
Vehicles [Member]
Property, plant and equipment	195	215
Construction in Progress [Member]
Property, plant and equipment	6,430	5,736
Property, plant and equipment	147,552	132,619
Less: accumulated depreciation and amortization	(84,459)	(72,822)
Property, plant and equipment, net	$ 63,093	$ 59,797

XML 65 R49.htm IDEA: XBRL DOCUMENT

Note 4 - Balance Sheet Components - Other Assets, Noncurrent (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Recoverable taxes from Brazilian government entities	$ 11,955	$ 8,887
Deposits on property and equipment, including taxes	292	243
Other	1,410	1,227
Total other assets	$ 13,657	$ 10,357

XML 66 R50.htm IDEA: XBRL DOCUMENT

Note 4 - Balance Sheet Components - Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Withholding tax related to conversion of related party notes	$ 4,964	$ 4,723
Professional services	5,406	4,017
SMA relocation accrual	4,380	3,641
Accrued interest	8,283	1,984
Tax-related liabilities	2,325	2,505
Accrued vacation	1,932	2,023
Payroll and related expenses	4,268	3,122
Deferred rent, current portion	1,110	1,111
Contractual obligations to contract manufacturers	680
Fair value swap short-term	586
Other	978	1,142
Total accrued and other current liabilities	$ 34,912	$ 24,268

XML 67 R51.htm IDEA: XBRL DOCUMENT

Note 5 - Debt and Mezzanine Equity (Details Textual) $ / shares in Units, BRL in Millions												1 Months Ended														3 Months Ended		5 Months Ended	6 Months Ended	9 Months Ended			12 Months Ended
	Jun. 24, 2016 USD ($)	May 10, 2016 USD ($)	Feb. 15, 2016 USD ($) $ / shares shares	Feb. 12, 2016 USD ($) $ / shares shares	Feb. 12, 2016 EUR (€)	Dec. 02, 2015 USD ($)	Nov. 30, 2015 USD ($)	Oct. 20, 2015 USD ($)	Oct. 14, 2015 USD ($) $ / shares shares	Jul. 29, 2015 USD ($) $ / shares shares	Apr. 02, 2015	Mar. 31, 2016 USD ($)	Mar. 31, 2016 EUR (€)	Feb. 29, 2016 USD ($) $ / shares shares	Nov. 30, 2015 USD ($)	Jul. 31, 2015 USD ($) $ / shares shares	Jun. 30, 2014 USD ($)	May 31, 2014 USD ($) $ / shares	Mar. 31, 2014 USD ($)	Jan. 31, 2014 USD ($) $ / shares	Oct. 31, 2013 USD ($) $ / shares	Aug. 31, 2013 USD ($) $ / shares shares	Jul. 31, 2012 USD ($)	Dec. 31, 2011 BRL	Nov. 30, 2010	Sep. 30, 2016 USD ($) $ / shares shares	Sep. 30, 2015 USD ($) shares	Sep. 30, 2016 USD ($) $ / shares shares	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($) $ / shares shares	Sep. 30, 2016 BRL	Sep. 30, 2015 USD ($) shares	Dec. 31, 2015 USD ($)	Sep. 30, 2016 BRL shares	Sep. 02, 2016 USD ($)	May 30, 2016 USD ($) $ / shares shares	Feb. 16, 2016 $ / shares	Dec. 31, 2015 BRL	Oct. 31, 2015 USD ($)	Jun. 30, 2015	Apr. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Jan. 31, 2015 USD ($) $ / shares	Jul. 31, 2014 USD ($) $ / shares	Apr. 30, 2014 USD ($) $ / shares	Dec. 31, 2013 USD ($)	Oct. 04, 2013	Sep. 30, 2013 USD ($) shares	Jul. 31, 2013 USD ($) $ / shares	Jun. 30, 2013 USD ($) $ / shares	Mar. 31, 2013 $ / shares	Sep. 14, 2012 USD ($) $ / shares	Jul. 31, 2012 BRL	Jul. 30, 2012 USD ($)	Jun. 30, 2012 USD ($)	Feb. 28, 2012 USD ($) $ / shares
The 2016 Convertible Note [Member] \| Convertible Subordinated Debt [Member] \| Minimum [Member]
Debt Instrument, Convertible Stock Price Trigger for Deferred Installments \| $ / shares																										$ 0.50		$ 0.50		$ 0.50
Debt Instrument, Convertible Threshold Consecutive Trading Days, Deferred Installments																														5 days	5 days
The 2016 Convertible Note [Member] \| Convertible Subordinated Debt [Member] \| Maximum [Member]
Debt Instrument, Convertible Stock Price Trigger for Deferred Installments \| $ / shares																										$ 1		$ 1		$ 1
Debt Instrument, Convertible Threshold Consecutive Trading Days, Deferred Installments																														30 days	30 days
The 2016 Convertible Note [Member] \| Convertible Subordinated Debt [Member] \| Scenario, Forecast [Member]
Proceeds from Convertible Debt																													$ 5,000,000
Debt Instrument, Face Amount, Contingent Second Closing																													$ 5,000,000
The 2016 Convertible Note [Member] \| Convertible Subordinated Debt [Member] \| Threshold 2 [Member]
Debt Instrument, Redemption Price, Percentage upon Triggering Event																														112.00%	112.00%
The 2016 Convertible Note [Member] \| Convertible Subordinated Debt [Member]
Debt Instrument, Monthly Installments, Percent of Installment Amount																														118.00%	118.00%
Debt Instrument, Events of Default, Percentage of Amount can be Redeemed by Holders																														118.00%	118.00%
Debt Instrument, Events of Fundamental Transaction, Percentage of Amount can be Redeemed by Holders																														118.00%	118.00%
Debt Instrument, Face Amount																																				$ 15,000,000
Debt Instrument, Convertible, Conversion Price \| $ / shares																																				$ 1.90
Proceeds from Convertible Debt		$ 9,900,000
Convertible Debt		$ 10,000,000																																	$ 2
Debt Instrument, Additional Common Stock Payment, Maximum Percent of Aggregate Amount																										50.00%		50.00%		50.00%				50.00%
Debt Instrument, Threshold Amount of Dollar-weighted Volume of Common Stock																										$ 200,000		$ 200,000		$ 200,000
Debt Instrument, Redemption Price, Percentage																														118.00%	118.00%
Convertible Debt, Length of Time from Date of Issuance, Threshold																														120 days	120 days
Hercules Credit Additional Amount [Member] \| Hercules Technology Growth Capital, Inc. (Hercules) [Member] \| Minimum [Member] \| Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate																	5.25%
Hercules Credit Additional Amount [Member] \| Hercules Technology Growth Capital, Inc. (Hercules) [Member] \| Maximum [Member] \| Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate																	8.50%
Hercules Credit Additional Amount [Member] \| Hercules Technology Growth Capital, Inc. (Hercules) [Member]
Debt Instrument, Additional Amount Required																	$ 5,000,000
Third Hercules Amendment [Member] \| Hercules Technology Growth Capital, Inc. (Hercules) [Member] \| Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate															6.25%
Third Hercules Amendment [Member] \| Hercules Technology Growth Capital, Inc. (Hercules) [Member] \| Portion of Debt Costs Owed in Connection with Expired Facility [Member]
Payments of Debt Issuance Costs							$ 750,000
Third Hercules Amendment [Member] \| Hercules Technology Growth Capital, Inc. (Hercules) [Member] \| Portion of Debt Costs Related to the Third Hercules Amendment [Member]
Payments of Debt Issuance Costs							$ 250,000
Third Hercules Amendment [Member] \| Hercules Technology Growth Capital, Inc. (Hercules) [Member]
Loans Payable						$ 31,700,000
Proceeds from Issuance of Long-term Debt															$ 10,960,000
Repayments of Long-term Debt						$ 9,100,000
Debt Instrument, Interest Rate, Stated Percentage							9.50%								9.50%
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid							$ 767,200								$ 767,200
Payments of Debt Issuance Costs							$ 1,000,000
Senior Secured Loan Facility [Member]
Loans Payable																										28,400,000		28,400,000		$ 28,400,000
Debt Instrument, Unamortized Discount																										100,000		$ 100,000		$ 100,000
Fidelity Convertible Notes [Member] \| Convertible Subordinated Debt [Member]
Convertible Notes Payable																																																								$ 25,000,000
Debt Instrument, Interest Rate, Effective Percentage																																																								3.00%
Fidelity Convertible Notes [Member]
Debt Instrument, Face Amount																																							$ 57,600,000
Debt Instrument, Convertible, Conversion Price \| $ / shares																																																								$ 7.0682
Debt Instrument, Repurchase Amount																																							8,800,000
Debt Instrument, Repurchased Face Amount																																							$ 9,700,000
Debt Instrument, Convertible, Number of Equity Instruments																														2,165,898	2,165,898
Convertible Promissory Note, Acquisition Right Amount Redeemable, Percentage																																																								101.00%
Convertible Promissory Note, Maximum Allowable Debt																																																								$ 200,000,000
Convertible Promissory Notes, Debt Percentage of Total Assets																																																								50.00%
Convertible Promissory Note, Maximum Amount of Secured Debt																																																								$ 125,000,000
Convertible Promissory Note, Secured Debt as a Percentage of Consolidated Total Assets																																																								30.00%
Convertible Promissory Note, Bridge Loan Amount, Convertible Promissory Note Covenants Waived																					$ 35,000,000
Additional Consideration for Covenant Waiving, Convertible Promissory Notes																					7,600,000
Rule 144A Convertible Note Offering [Member] \| Convertible Debt Securities [Member]
Debt Instrument, Interest Rate, Effective Percentage																		6.50%
Rule 144A Convertible Note Offering [Member] \| Numerator [Member]
Debt Instrument, Convertible, Conversion Ratio																		267.037
Rule 144A Convertible Note Offering [Member] \| Denominator [Member]
Debt Instrument, Convertible, Conversion Rate, Principle Amount \| $ / shares																		$ 1,000
Rule 144A Convertible Note Offering [Member] \| Affiliated Entity [Member]
Debt Instrument, Interest Rate, Stated Percentage																		6.50%
Debt Instrument, Face Amount																		$ 57,600,000
Debt Instrument, Repurchase Amount																		18,300,000
Debt Instrument, Repurchased Face Amount																		22.90
Amount of Convertible Debt Purchased by Affiliated Entities																		$ 24,700,000
Rule 144A Convertible Note Offering [Member]
Debt Instrument, Convertible, Conversion Price \| $ / shares																		$ 3.74
Convertible Note Offering																		$ 75,000,000
Additional Convertible Note Offering																		15,000,000
Proceeds from Convertible Debt																		72,000,000
Proceeds from Convertible Debt Used to Repay Previously Issued Convertible Debt																		$ 9,700,000
Debt Instrument, Convertible, Threshold Trading Days																		20
Debt Instrument, Convertible, Threshold Consecutive Trading Days																		30 days
Debt Instrument, Convertible, Threshold Days for Conversion Notification																		5 days
Convertible Note Substantial Change, Discount Rate Used in Calculate Value of Remaining Interest Payments																		0.75%
Convertible Note Substantial Change, Percentage of Principal Repurchase Price																		100.00%
Convertible Senior Notes, 9.5% [Member]
Debt Instrument, Interest Rate, Stated Percentage									9.50%
Debt Instrument, Face Amount									$ 57,600,000
Debt Instrument, Convertible, Conversion Price \| $ / shares									$ 2.25
Debt Instrument, Repurchase Amount				$ 3,700,000								$ 3,700,000
Debt Instrument, Convertible, Number of Equity Instruments									38,415,626
Convertible Promissory Note, Maximum Allowable Debt									$ 200,000,000
Convertible Promissory Note, Maximum Amount of Secured Debt									$ 65,000,000
Convertible Promissory Note, Secured Debt as a Percentage of Consolidated Total Assets									30.00%
Proceeds from Convertible Debt								$ 54,400,000
Debt Instrument, Convertible, Conversion Rate, Principle Amount \| $ / shares									$ 1,000					$ 1,000														$ 1,000
Convertible Note Substantial Change, Discount Rate Used in Calculate Value of Remaining Interest Payments									0.75%
Convertible Note Substantial Change, Percentage of Principal Repurchase Price									100.00%
Debt Instrument, Convertible, Conversion Rate, Shares \| shares									443.6557					446.6719														446.8707
Debt Instrument, Convertible Percentage of Average Price Per Share the Stock will be Valued upon Early Conversion									92.50%
Number of Trading Days Notes Become Convertible									10 days
Debt Restrictions, Maximum Outstanding Debt									$ 25,000,000
Long-term Debt																										$ 17,800,000		$ 17,800,000		$ 17,800,000
Class of Warrant or Right, Term				5 years	5 years
Convertible Senior Notes, 6.5% [Member]
Debt Instrument, Repurchase Amount								18,300,000
Debt Instrument, Repurchased Face Amount								22,900,000
Convertible Senior Notes, 3% [Member]
Debt Instrument, Repurchase Amount								8,800,000
Debt Instrument, Repurchased Face Amount								$ 9,700,000
Total Purchase Agreement [Member] \| Total [Member]
Debt Instrument, Face Amount																							$ 105,000,000
Unsecured Senior Convertible Promissory Notes [Member] \| Total [Member]
Extinguishment of Debt, Amount				$ 1,300,000
Unsecured Senior Convertible Promissory Notes [Member] \| Initial Closing [Member] \| Total [Member] \| New Funding [Member]
Debt Instrument, Face Amount																																																						$ 15,000,000
Unsecured Senior Convertible Promissory Notes [Member] \| Initial Closing [Member] \| Total [Member] \| Diesel Research and Development Funding [Member]
Debt Instrument, Face Amount																																																						23,300,000
Unsecured Senior Convertible Promissory Notes [Member] \| Initial Closing [Member] \| Total [Member]
Debt Instrument, Interest Rate, Stated Percentage																							1.50%																														1.50%
Debt Instrument, Face Amount																																																				$ 15,000,000		$ 38,300,000
Number of Installments																							2
Unsecured Senior Convertible Promissory Notes [Member] \| Initial Closing [Member]
Debt Instrument, Convertible, Conversion Price \| $ / shares																																																				$ 7.0682
Unsecured Senior Convertible Promissory Notes [Member] \| Second Closing [Member] \| Total [Member] \| Related Party Convertible Notes [Member]
Debt Instrument, Face Amount																																																	$ 20,000,000	$ 10,000,000
Unsecured Senior Convertible Promissory Notes [Member] \| Second Closing [Member] \| Total [Member]
Number of Installments																							2
Unsecured Senior Convertible Promissory Notes [Member] \| Second Closing [Member] \| Related Party Convertible Notes [Member]
Debt Instrument, Convertible, Conversion Price \| $ / shares																																																	$ 3.08
Unsecured Senior Convertible Promissory Notes [Member] \| Two Installments in Second Closing [Member] \| Total [Member] \| Related Party Convertible Notes [Member]
Debt Instrument, Face Amount																																																	$ 30,000,000
Unsecured Senior Convertible Promissory Notes [Member] \| Third Closing [Member] \| Total [Member]
Debt Instrument, Face Amount																																											$ 10,850,000	$ 10,850,000
Number of Installments																							2
Unsecured Senior Convertible Promissory Notes [Member] \| Third Closing [Member]
Debt Instrument, Convertible, Conversion Price \| $ / shares																																											$ 4.11
Unsecured Senior Convertible Promissory Notes [Member] \| Two Installments In Third Closing [Member] \| Total [Member]
Debt Instrument, Face Amount																																											$ 21,700,000	$ 21,700,000
Debt Instrument, Convertible, Conversion Price \| $ / shares																																												$ 4.11
Unsecured Senior Convertible Promissory Notes [Member] \| Total [Member] \| Related Party Convertible Notes [Member]
Debt Instrument, Face Amount																																																	30,000,000	$ 10,000,000
Unsecured Senior Convertible Promissory Notes [Member] \| Total [Member]
Debt Instrument, Face Amount																																														$ 69,000,000
March 2013 Letter Agreement [Member] \| Minimum [Member] \| Total [Member]
Debt Instrument, Convertible, Conversion Price \| $ / shares																																																			$ 3.08
March 2013 Letter Agreement [Member] \| Total [Member]
Debt Instrument, Convertible, Conversion Price \| $ / shares																																																		$ 3.08	7.0682
Debt Instrument Closing Price Plus Incremental Rate \| $ / shares																																																			$ 0.01
Senior Secured Convertible Note [Member] \| Total [Member]
Debt Instrument, Interest Rate, Stated Percentage																																														1.50%
July 2012 Agreements [Member] \| Total [Member]
Debt Instrument, Face Amount																																												$ 10,850,000
Debt Instrument, Convertible, Conversion Price \| $ / shares																																													$ 7.0682
March 2014 Letter Agreement [Member] \| Two Installments In Third Closing [Member] \| Total [Member]
Debt Instrument, Convertible, Conversion Price \| $ / shares																																											$ 4.11
March 2014 Letter Agreement [Member] \| Total [Member]
Debt Instrument, Convertible, Conversion Price \| $ / shares																																													$ 4.11
Convertible Debt																																													$ 75,000,000
Unsecured Promissory Notes, 2016 [Member] \| Total [Member]
Extinguishment of Debt, Amount												1,300,000
March 2016 R&D Note [Member]
Extinguishment of Debt, Amount												5,000,000
Replacement Notes [Member]
Debt Instrument, Unamortized Discount												0																					$ 0
Debt Instrument, Interest Rate, Effective Percentage																										1.50%		1.50%		1.50%				1.50%
Debt Instrument, Convertible, Conversion Price \| $ / shares																										$ 3.08		$ 3.08		$ 3.08
Convertible Promissory Note, Maximum Allowable Debt																										$ 200,000,000		$ 200,000,000		$ 200,000,000
Convertible Promissory Notes, Debt Percentage of Total Assets																										50.00%		50.00%		50.00%				50.00%
Convertible Promissory Note, Maximum Amount of Secured Debt																										$ 125,000,000		$ 125,000,000		$ 125,000,000
Convertible Promissory Note, Secured Debt as a Percentage of Consolidated Total Assets																										30.00%		30.00%		30.00%				30.00%
Long-term Debt												$ 3,700,000														$ 3,700,000		$ 3,700,000		$ 3,700,000			5,000,000
Debt Instrument Default Rate																										2.50%		2.50%		2.50%				2.50%
Percentage of Principal Amount of Notes, Required to Be Repaid in Change of Control																														101.00%	101.00%
August 2013 Convertible Notes [Member] \| Private Placement [Member]
Debt Instrument, Face Amount																																																$ 110,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares																																																1,000,000
August 2013 Convertible Notes [Member] \| Total [Member] \| First Tranche [Member]
Cancellation of Convertible Debt																						$ 7,600,000
August 2013 Convertible Notes [Member] \| Total [Member] \| Second Tranche [Member]
Cancellation of Convertible Debt																						$ 5,400,000
August 2013 Convertible Notes [Member] \| Total [Member] \| Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares																						1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares																						$ 0.01
August 2013 Convertible Notes [Member] \| Total [Member]
Cancellation of Convertible Debt																						$ 13,000,000
August 2013 Convertible Notes [Member] \| Total and Temasek [Member] \| First Tranche [Member]
Debt Instrument, Face Amount																						42,600,000
August 2013 Convertible Notes [Member] \| Total and Temasek [Member] \| Second Tranche [Member]
Debt Instrument, Face Amount																						30,400,000
August 2013 Convertible Notes [Member] \| Total and Temasek [Member]
Debt Instrument, Face Amount																						$ 73,000,000
Private Placement Convertible Notes, Period																						2 years
Debt Instrument, Number of Tranches																						2
August 2013 Convertible Notes [Member] \| Temasek [Member] \| Second Tranche [Member]
Proceeds from Convertible Debt																						$ 25,000,000
August 2013 Convertible Notes [Member] \| Temasek [Member]
Extinguishment of Debt, Amount																						$ 35,000,000
Bridge Loan																					35,000,000
Temasek Bridge Loan [Member] \| Temasek [Member]
Debt Instrument, Interest Rate, Stated Percentage																																															5.50%
First Tranche [Member] \| Related Party Convertible Notes [Member] \| Total [Member]
Debt Instrument, Face Amount																					51,800,000
Extinguishment of Debt, Amount																					9,200,000
First Tranche [Member] \| Related Party Convertible Notes [Member] \| Temasek [Member]
Extinguishment of Debt, Amount																					$ 35,000,000
First Tranche [Member] \| Related Party Convertible Notes [Member]
Debt Instrument, Convertible, Conversion Price \| $ / shares																					$ 2.44
Proceeds from Convertible Debt																					$ 7,600,000
Gain (Loss) on Extinguishment of Debt																					(19,900,000)
Cancellation of Convertible Debt																					$ 44,200,000
Convertible Promissory Notes, Period After Which Notes Will Be Due																					5 years
Convertible Notes, Discount Percentage to Determine Conversion Price																					15.00%
Convertible Note Discount, Number of Days for Trailing Weighted-average Closing Price																					60 days
Convertible Notes, Period After Which Convertible at the Option of Holder																					1 year 180 days
Plant Manufacturing Production, Product Sales, Percentage																					5.00%
Debt Instrument, Convertible, Conversion Price, Interest Accrued, Rate Applicable to the First 180 Days																					6.50%
Debt Instrument, Convertible, Conversion Price, Interest Accrued Thereafter																					8.00%
Debt Instrument, Convertible, Conversion Price, Interest Accrued for Defaults																					6.50%
Convertible Notes, Period Over Which Interest is Payable in Kind																					2 years 180 days
Convertible Notes, Recurring Term of Option to Prepay After Initial Payment Period																					180 days
Convertible Notes, Initial Prepayment Term																					2 years 180 days
Second Tranche [Member] \| Related Party Convertible Notes [Member]
Future Cancellation of Debt, Amount																					$ 9,200,000
The Second Tranche [Member] \| Related Party Convertible Notes [Member] \| Temasek [Member]
Convertible Notes Purchased																				$ 25,000,000
The Second Tranche [Member] \| Related Party Convertible Notes [Member] \| Wolverine [Member]
Convertible Notes Purchased																				3,000,000
The Second Tranche [Member] \| Related Party Convertible Notes [Member] \| Total [Member]
Convertible Notes Purchased																				6,000,000
The Second Tranche [Member] \| Related Party Convertible Notes [Member]
Debt Instrument, Face Amount																				$ 34,000,000
Tranche I and Tranche II Notes [Member] \| Related Party Convertible Notes [Member]
Debt Instrument, Unamortized Discount																										$ 0		$ 0		$ 0			0
Debt Instrument, Convertible, Conversion Price \| $ / shares																$ 1.42																				$ 1.14	$ 1.40
Convertible Debt																										21,700,000		21,700,000		21,700,000			23,300,000
Debt Conversion, Original Debt, Amount																$ 71,000,000
Debt Conversion, Converted Instrument, Shares Issued \| shares																30,860,000
Percentage of Principal Amount of Notes, Required to Be Repaid in Change of Control																				101.00%
Tranche I and Tranche II Notes [Member] \| Total [Member]
Convertible Notes Payable										$ 15,300,000
ABC Brasil Agreement [Member] \| Banco ABC Brasil S.A. (ABC) [Member]
Additional Export Financing Agreement																			$ 2,200,000							0		0		0			1,600,000								$ 1,600,000
Rule 144A Convertible Notes [Member] \| Temasek [Member]
Convertible Notes Payable										10,000,000
Rule 144A Convertible Notes [Member] \| Total [Member]
Convertible Notes Payable										$ 9,700,000
June 2016 Private Placement [Member]
Debt Instrument, Interest Rate, Stated Percentage	13.50%
Debt Instrument, Face Amount	$ 5,000,000
Proceeds from Issuance of Private Placement	$ 5,000,000
Related Party and Non-Related Party Convertible Debt [Member]
Debt Instrument, Unamortized Discount																										33,000,000		33,000,000		33,000,000
Debt Issuance Costs, Net																										3,000,000		3,000,000		3,000,000
Related Party Convertible Notes [Member] \| The Second Tranche [Member]
Debt Instrument, Convertible, Conversion Price \| $ / shares																				$ 2.87
Convertible Promissory Notes, Period After Which Notes Will Be Due																				5 years
Convertible Note Discount, Number of Days for Trailing Weighted-average Closing Price																				60 days
Debt Instrument, Convertible, Conversion Price, Interest Accrued, Rate Applicable to the First 180 Days																				13.00%
Debt Instrument, Convertible, Conversion Price, Interest Accrued Thereafter																				16.00%
Debt Instrument, Convertible, Conversion Price, Interest Accrued for Defaults																				12.00%
Convertible Notes, Recurring Term of Option to Prepay After Initial Payment Period																				180 days
Convertible Notes Exchanged and Cancelled																				$ 6,000,000
Debt Instrument, Term																				1 year
Debt Instrument, Convertible, Conversion Price, Interest Accrued																				10.00%
Debt Instrument, Convertible, Conversion Price, Interest Period																				3 years
Related Party Convertible Notes [Member]
Convertible Debt																										40,600,000		40,600,000		40,600,000			42,800,000
Gain (Loss) on Extinguishment of Debt																				$ (9,400,000)
Long-term Debt																										40,611,000		40,611,000		40,611,000			42,749,000
Debt Instrument, Debt Discount, Related Party																										2,600,000		2,600,000		2,600,000			1,900,000
Rule 144A Related Party Convertible Notes [Member]
Convertible Debt																										15,300,000		15,300,000		15,300,000			14,600,000
Debt Instrument, Debt Discount, Related Party																										2,400,000		2,400,000		2,400,000			1,600,000
Loans Payable [Member] \| Nossa Caixa and Banco Pine Agreements [Member]
Long-term Debt																										11,700,000		11,700,000		11,700,000			11,000,000	BRL 37.9				BRL 43.0
Loans Payable [Member]
Long-term Debt																										12,954,000		12,954,000		12,954,000			13,606,000
Unsecured Promissory Notes, 2016 [Member] \| Private Placement February 2016 [Member]
Debt Instrument, Face Amount			$ 2,000,000	$ 18,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares			285,714	2,571,428
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 0.01	$ 0.01
Hercules Technology Growth Capital, Inc. (Hercules) [Member] \| Minimum [Member] \| Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate																			6.25%
Hercules Technology Growth Capital, Inc. (Hercules) [Member] \| Maximum [Member] \| Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate																			9.50%
Hercules Technology Growth Capital, Inc. (Hercules) [Member]
Loans Payable																			$ 25,000,000
Debt Instrument, Prepayment Penalty, Percentage																			1.00%
Debt Instrument, Facility Charge, Percentage																			1.00%																					5.00%
Debt Instrument, End of Term Fee, Percentage																			10.00%
Long-term Line of Credit																			$ 25,000,000
Debt Instrument, Forbearance Fee, Forgiven																	10,000,000
Debt Instrument, Required Equity Financing, Amount																	$ 50,000,000
Debt Instrument, Unencumbered, Unrestricted, Cash Required, Percentage																	50.00%
Line of Credit Facility, Maximum Borrowing Capacity																																										$ 15,000,000
Line of Credit Facility, Amount to be Raised Through Equity Triggering Withdrawal of the Credit Facility																																										$ 20,000,000
Line of Credit Facility, Commitment Fee Percentage											3.00%
Nossa Caixa and Banco Pine Agreements [Member]
Debt Instrument, Interest Rate, Stated Percentage																							5.50%																														5.50%
Debt Instrument, Face Amount																										$ 16,000,000		$ 16,000,000		16,000,000				BRL 52.0
Collateral Provided by Company Certain Equipment and Other Tangible Assets, Amount																														$ 20,900,000	BRL 68.0
Certain Farnesene Production Assets Pledged as Collateral for Loans \| BRL																																																					BRL 52.0
Debt Instrument, Period of Interest Only QuarterlyPayments																							2 years
Banco Pine [Member]
Debt Instrument, Face Amount \| BRL																																																					22.0
Nossa Caixa [Member]
Debt Instrument, Face Amount \| BRL																																																					BRL 30.0
Temasek [Member] \| If Total R&D Warrant is Exercised in Full [Member] \| Temasek Warrant Three [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares										880,339
Temasek [Member] \| Temasek Warrant 1 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares										14,677,861
Temasek [Member] \| Temasek Warrant 2 [Member]
Class of Warrant or Right, Numerator One										30.60%
Class of Warrant or Right, Denominator One										69.40%
Class of Warrant or Right, Numerator Two										13.30%
Class of Warrant or Right, Denominator Two										86.70%
Temasek [Member] \| Temasek Warrant Three [Member]
Class of Warrant or Right, Term										10 years
Class of Warrant or Right, Common Stock Shares Used In Calculation \| shares										880,339
Class of Warrant or Right, Threshold Number of Securities \| shares										2,000,000
Temasek [Member] \| The 2013 Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares										1,000,000				127,194												12,700,244		12,700,244		12,700,244				12,700,244		2,335,342
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares										$ 0.01
Class of Warrant or Right, Outstanding \| shares																										2,462,536		2,462,536		2,462,536				2,462,536
Temasek [Member]
Debt Conversion, Original Debt, Amount										$ 71,000,000
Debt Conversion, Converted Instrument, Shares Issued \| shares										30,860,633
Total [Member] \| Total Funding Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares										18,924,191
Class of Warrant or Right, Term										5 years
Total [Member] \| Total R&D Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares										2,000,000
Total [Member] \| Temasek Warrant 2 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares										2,000,000
Total [Member]
Convertible Notes Payable										$ 25,000,000
Debt Conversion, Original Debt, Amount										$ 70,000,000
Debt Conversion, Converted Instrument, Shares Issued \| shares										30,434,782
Extinguishment of Debt, Amount \| €					€ 50,000
Total and Temasek [Member]
Debt Instrument, Convertible, Conversion Price \| $ / shares										$ 2.30
Interest Expense, Debt																																	39,200,000
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares																										$ 0.01		$ 0.01		$ 0.01
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares																										$ 10.67		$ 10.67		$ 10.67
TJLP Adjustment Factor [Member] \| FINEP Credit Facility [Member] \| Threshold Met [Member]
Debt Instrument, Basis Spread on Variable Rate																									5.00%
TJLP Adjustment Factor [Member]
DebtInstruementInterestRateOfTheCentralBankOfBrazilUsedAsAThreshold																									6.00%
Private Placement February 2016 [Member] \| Foris Ventures, LLC [Member]
Proceeds from Issuance of Private Placement			$ 16,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares			2,285,714
Private Placement February 2016 [Member]
Line of Credit Facility, Maximum Borrowing Capacity														$ 1,000,000
Debt Instrument, Interest Rate, Stated Percentage			13.50%
Debt Instrument, Face Amount														20,000,000
Proceeds from Issuance of Private Placement			$ 2,000,000	$ 18,000,000										$ 20,000,000
Unsecured Senior Convertible Promissory Notes [Member] \| Total [Member] \| Related Party Convertible Notes [Member]
Debt Instrument, Face Amount																																																	$ 20,000,000
BNDES Credit Facility [Member] \| First Tranche [Member]
Line of Credit Facility, Maximum Borrowing Capacity \| BRL																								BRL 19.1
BNDES Credit Facility [Member] \| The Second Tranche [Member]
Line of Credit Facility, Maximum Borrowing Capacity \| BRL																								BRL 3.3
Line of Credit Facility Bank Guarantee Percentage																								90.00%
Line of Credit Facility, Borrowings Above Which is New Tranche \| BRL																								BRL 19.1
BNDES Credit Facility [Member]
Long-term Line of Credit																										$ 1,500,000		$ 1,500,000		$ 1,500,000			1,900,000	BRL 4.8				7.6
Line of Credit Facility, Maximum Borrowing Capacity																								BRL 22.4		6,900,000		6,900,000		6,900,000
Debt Instrument, Interest Rate, Stated Percentage																								7.00%
Debt Instrument, Number of Monthly Installments																								60
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage																								0.10%
Collateral Provided by Company Certain Equipment and Other Tangible Assets, Amount																								BRL 24.9						7,700,000
Line of Credit Facility Bank Guarantee Percentage																								10.00%
Guarantor Obligations, Liquidation Proceeds, Percentage																								130.00%
FINEP Credit Facility [Member] \| Threshold Met [Member]
Debt Instrument, Interest Rate, Stated Percentage																									11.00%
FINEP Credit Facility [Member]
Long-term Line of Credit																										800,000		800,000		800,000			900,000	2.5				BRL 3.4
Line of Credit Facility, Maximum Borrowing Capacity																										$ 2,000,000		$ 2,000,000		$ 2,000,000				BRL 6.4
Debt Instrument, Interest Rate, Stated Percentage																									5.00%
Debt Instrument, Number of Monthly Installments																									81
DebtDefualtPenaltyAndFineOnObligationInDefaultPercentage																									10.00%
Debt Instrument Interest On Late Balance Percentage Per Month																									1.00%
Total [Member]
Extinguishment of Debt, Amount \| €													€ 50,000
Letter of Credit [Member]
Restricted Cash and Cash Equivalents, Noncurrent																																	1,000,000																						$ 1,000,000
Total [Member] \| JVCO Joint Venture [Member]
Equity Method Investment, Ownership Percentage by Counterparty				75.00%								75.00%
Total [Member]
Convertible Debt																$ 5,000,000
Debt Conversion, Original Debt, Amount																$ 70,000,000
Debt Conversion, Converted Instrument, Shares Issued \| shares																30,400,000
JVCO Joint Venture [Member]
Equity Method Investment, Ownership Percentage				25.00%								25.00%														25.00%		25.00%		25.00%				25.00%
Exchange Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares										$ 0.01
Reduction in Noncurrent Debt [Member]
Prior Period Reclassification Adjustment																																	2,800,000
Reduction in Current Debt [Member]
Prior Period Reclassification Adjustment																																	1,400,000
Reduction in Noncurrent Assets [Member]
Prior Period Reclassification Adjustment																																	2,800,000
Reduction in Prepaid Expenses and Other Current Assets [Member]
Prior Period Reclassification Adjustment																																	1,400,000
Proceeds from Issuance of Long-term Debt																														$ 13,275,000		$ 1,607,000
Repayments of Long-term Debt																														7,442,000		11,249,000
Proceeds from Issuance of Private Placement																																25,000,000
Debt Instrument, Unamortized Discount																										$ 36,100,000		$ 36,100,000		36,100,000
Gain (Loss) on Extinguishment of Debt												$ 4,200,000														(217,000)	$ (5,984,000)			(866,000)		$ (5,984,000)
Long-term Debt																										$ 175,631,000		$ 175,631,000		$ 175,631,000			151,974,000
Class of Warrant or Right, Term																														5 years 328 days	5 years 328 days
Class of Warrant or Right, Outstanding \| shares																										14,663,411	50,699,368	14,663,411		14,663,411		50,699,368		14,663,411
Letters of Credit Outstanding, Amount																																																							$ 1,000,000
Restricted Cash and Cash Equivalents, Noncurrent																										$ 958,000		$ 958,000		$ 958,000			$ 957,000

XML 68 R52.htm IDEA: XBRL DOCUMENT

Note 5 - Debt and Mezzanine Equity - Debt Components (Details) - USD ($)
$ in Thousands

Sep. 30, 2016

Dec. 31, 2015

BNDES Credit Facility [Member]

$ 28,438

$ 31,590

FINEP Credit Facility [Member]

1,471

1,956

777

840

Credit Facility [Member]

30,686

34,386

Convertible Debt [Member]

760

68,533

61,233

53,176

40,611

42,749

Related Party Loan Payable [Member]

37,000

22,847

Loans Payable [Member]

12,954

13,606

9,679

175,631

151,974

Less: current portion

(75,016)

(36,281)

100,615

115,693

Mezzanine equity

^[1]

$ 5,000

[1]	See Note 8, "Significant Agreements" for details regarding the Bill & Melinda Gates Foundation Investment, classified as mezzanine equity.

XML 69 R53.htm IDEA: XBRL DOCUMENT

Note 5 - Debt and Mezzanine Equity - Long-term Debt Instruments (Details) - USD ($)
$ in Thousands

Sep. 30, 2016

Dec. 31, 2015

$ 312

4,837

13,937

26,080

45,166

^[1]

(4,555)

Less: current portion present value of minimum debt payments

40,611

(3,611)

Convertible Debt [Member]

37,000

3,240

23,562

17,736

79,937

124,475

^[1]

(55,942)

Less: current portion present value of minimum debt payments

68,533

(15,357)

53,176

Loans Payable [Member]

1,770

2,870

2,450

2,342

2,234

3,314

14,980

^[1]

(2,026)

Less: current portion present value of minimum debt payments

12,954

(3,275)

Related Party Loan Payable [Member]

9,679

844

26,257

27,101

^[1]

(4,254)

Less: current portion present value of minimum debt payments

22,847

(22,847)

Credit Facility [Member]

33,234

1,551

322

35,185

^[1]

(4,499)

Less: current portion present value of minimum debt payments

30,686

(29,926)

760

39,400

59,077

34,445

108,437

2,234

3,314

246,907

^[1]

(71,276)

Less: current portion present value of minimum debt payments

175,631

(75,016)